FibroGen Announces 1-for-25 Reverse Stock Split
- SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen's common stock will begin trading on a split-adjusted basis on June 17, 2025, when the markets open, under the Company's existing trading symbol “FGEN,” with the new CUSIP number 31572Q881.
- 06/12/2025
|
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
- SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.
- 06/09/2025
|
FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - Chief Executive Officer David DeLucia - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Matthew Keller - H.C. Wainwright Operator Good day and thank you for standing by.
- 05/12/2025
|
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
- FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of $0.03. This compares to loss of $0.33 per share a year ago.
- 05/12/2025
|
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
- SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2025 and provided an update on the company's recent developments.
- 05/12/2025
|
Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)
- Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Duchenne Muscular Dystrophy - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Duchenne Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report Highlights Companies and academics are working to assess challenges and seek opportunities that could influence R&D Duchenne Muscular Dystrophy. The therapies under development are focused on novel approaches to treat/improve Duchenne Muscular Dystrophy. Duchenne Muscular Dystrophy Emerging Drugs
- 05/08/2025
|
FibroGen to Report First Quarter 2025 Financial Results
- SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 05/05/2025
|
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
- SAN FRANCISCO, April 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025.
- 04/02/2025
|
FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q4 2024 Earnings Conference Call March 17, 2025 5:00 PM ET Company Participants Joanne Greller - LifeSci Advisors Thane Wettig - CEO David DeLucia - CFO Conference Call Participants Andy Sieh - William Blair Matthew Keller - H.C. Wainwright Operator Hello everyone, and welcome to the FibroGen Fourth Quarter and Full Year 2024 Earnings Conference Call.
- 03/17/2025
|
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
- SAN FRANCISCO, March 17, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2024 and provided an update on the company's recent developments.
- 03/17/2025
|
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results
- SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2024 financial results on Monday, March 17 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 03/03/2025
|
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million
- FibroGen Inc. FGEN stock is trading higher on Thursday. The company announced the sale of its China subsidiary to AstraZeneca Plc AZN for approximately $160 million.
- 02/20/2025
|
FibroGen sells China unit to AstraZeneca in deal worth $160 million
- FibroGen said on Thursday that it has sold its China unit to AstraZeneca for about $160 million.
- 02/20/2025
|
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million
- SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.
- 02/20/2025
|
FibroGen Appoints David DeLucia as Chief Financial Officer
- SAN FRANCISCO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of David DeLucia to Chief Financial Officer (CFO), effective December 16, 2024. The company previously announced that Juan Graham would step down on December 15, 2024.
- 12/16/2024
|
FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A & IR Thane Wettig - CEO Juan Graham - CFO Conference Call Participants Andy Hsieh - William Blair Operator Good day and welcome to the FibroGen Third Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
- 11/12/2024
|
FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates
- FibroGen (FGEN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.52 per share a year ago.
- 11/12/2024
|
FibroGen Reports Third Quarter 2024 Financial Results
- SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2024 and provided an update on the company's recent developments.
- 11/12/2024
|
FibroGen to Report Third Quarter 2024 Financial Results
- SAN FRANCISCO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2024 financial results on Tuesday, November 12 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 11/04/2024
|
FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET Company Participants David DeLucia - CFA Vice President, Corporate FP&A & Investor Relations Thane Wettig - Chief Executive Officer Deyaa Adib - Chief Medical Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President, China Operations Conference Call Participants Dalton Greenwood - William Blair Dina Ramadane - Bank of America Paul Choi - Goldman Sachs Operator Good day and welcome to the FibroGen Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
- 08/09/2024
|
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
- FibroGen (FGEN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.65 per share a year ago.
- 08/06/2024
|
One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program
- FibroGen Inc. FGEN saw its share price plummet after the release of topline results from two late-stage trials evaluating the efficacy and safety of pamrevlumab in pancreatic cancer patients.
- 07/31/2024
|
FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts
- FibroGen (NASDAQ: FGEN ) layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. FibroGen says that it is going into a cost-saving mode that will result in layoffs for 75% of its U.S. employees.
- 07/31/2024
|
Why Is FibroGen (FGEN) Stock Down 44% Today?
- FibroGen (NASDAQ: FGEN ) stock is falling hard on Wednesday after the biopharmaceutical company reported results from failed clinical trials. The first failed clinical trial covers the treatment of metastatic pancreatic cancer with pamrevlumab.
- 07/31/2024
|
FibroGen to Report Second Quarter 2024 Financial Results
- SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2024 financial results on Tuesday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 07/30/2024
|
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
- SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen's immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron's anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.
- 06/03/2024
|
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
- SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) of FG-3165, a galectin-9 (Gal9) targeted monoclonal antibody under development for treatment of solid tumors characterized by high Gal9 levels of expression.
- 06/03/2024
|
7 Penny Biotech Stocks to Triple Your Investment
- One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks.
- 05/28/2024
|
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting
- SAN FRANCISCO, May 23, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive interim results from the dose escalation portion of the investigator-sponsored Phase 1b/2 study conducted by the University of California San Francisco of FG-3246 (FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with a MMAE-containing payload, in combination with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 05/23/2024
|
FibroGen to Participate in Upcoming Investor Conferences
- SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the company's management will participate in the following investor conferences:
- 05/07/2024
|
FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants David DeLucia - VP, Corporate FP&A and IR Thane Wettig - CEO Deyaa Adib - CMO Juan Graham - CFO Chris Chung - SVP, China Operations Conference Call Participants Andy Hsieh - William Blair Paul Choi - Goldman Sachs Operator Good day and thank you for standing by. Welcome to the FibroGen's First Quarter 2024 Earnings Conference Call.
- 05/06/2024
|
FibroGen Reports First Quarter 2024 Financial Results
- SAN FRANCISCO, May 06, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2024 and provided an update on the company's recent developments.
- 05/06/2024
|
FibroGen to Report First Quarter 2024 Financial Results
- SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 04/29/2024
|
FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
- SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that clinical data from the dose escalation portion of the Phase 1b/2 study of FG-3246 in combination with enzalutamide in patients with metastatic castration resistant prostate cancer have been selected for a poster presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31-June 4, 2024 in Chicago, Illinois.
- 04/24/2024
|
FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
- SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload, in a dose-escalation and dose-expansion trial enrolling patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors have progressed on at least one androgen receptor-signaling inhibitor (ARSI).
- 04/02/2024
|
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
- SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern Time. Company management will also participate in virtual one-on-one meetings with investors during the conference.
- 03/26/2024
|
3 Nightmare Nasdaq Stocks Not Worth Holding Another Day
- Stocks are at the mercy of many factors, and often, prices are just a poor earnings report or a negative headline away from a significant drop. There are times when nobody has any way of preparing.
- 03/20/2024
|
FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer
- SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024.
- 03/11/2024
|
FibroGen regains rights to anemia drug from AstraZeneca
- FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.
- 02/26/2024
|
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
- • Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) expected in 1Q 2024 • FibroGen regains rights to roxadustat from AstraZeneca in the United States and other AstraZeneca territories, except China and South Korea • FY 2023 total net revenue of $147.8 million, an increase of 5% year over year • Robust roxadustat volume growth of 41% in China in FY 2023 compared to FY 2022 • Successful execution of cost reduction plan; $248.1 million in cash provides cash runway into 2026 SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the fourth quarter and full year 2023 and provided an update on the company's recent developments. “We are extremely excited about the company's prospects in 2024,” said Thane Wettig, Chief Executive Officer, FibroGen.
- 02/26/2024
|
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
- The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced today that FibroGen and AstraZeneca have agreed to terminate the U.S./RoW roxadustat collaboration agreement entered into on July 30, 2013, under which AstraZeneca held development and commercialization rights in the United States and other territories outside of China not licensed to Astellas Pharma Inc. Pursuant to a termination and transition agreement entered into between the parties, AstraZeneca is returning all U.S./RoW roxadustat rights to FibroGen (with the exception of South Korea) and providing certain assistance during a transition period. FibroGen's collaboration agreement with AstraZeneca for roxadustat in China remains in place and roxadustat remains the leader in China by brand value share in the chronic kidney disease (CKD) anemia category.
- 02/26/2024
|
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
- SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 02/20/2024
|
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
- SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET. To register, click here .
- 02/05/2024
|
FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer
- SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Topline data from this registration study is anticipated in the second quarter of 2024.
- 01/25/2024
|
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of long-term stockholders following a class action complaint that was filed against FibroGen on April 12, 2021 with a Class Period from December 20, 2018 to July 15, 2021. Our investigation concerns whether the board of directors of FibroGen have breached their fiduciary duties to the company. The compl.
- 12/26/2023
|
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
- A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047 ǂ ).
- 12/09/2023
|
FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript
- FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript
- 11/06/2023
|
FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 11/06/2023
|
FibroGen Reports Third Quarter 2023 Financial Results
- SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company's recent developments.
- 11/06/2023
|
FibroGen to Report Third Quarter 2023 Financial Results
- SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 10/23/2023
|
7 Stocks to Sell Before the Axe Falls
- While a contentious topic, investors seeking long-term success must frequently consider stocks to sell. Similar to changing the oil in a combustion-powered car, you've got to keep the overall machinery running well.
- 10/19/2023
|
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%
- FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint.
- 08/30/2023
|
FibroGen stock plummets as muscular dystrophy drug trial fails
- FibroGen Inc (NASDAQ:FGEN) plummeted some 27% lower in Wednesday's early deals after revealing that its intended treatment for Duchenne muscular dystrophy failed to achieve primary and secondary endpoints in a clinical study. In the trial, the potential drug, pamrevlumab, had targeted an improvement in an ambulatory assessment score at 52 weeks in boys with DMD, ages six through 11.
- 08/30/2023
|
FibroGen shares fall after failure in late-stage study of Duchenne muscular dystrophy treatment
- Shares of FibroGen Inc. FGEN, +3.23% fell 23% premarket on Wednesday after the company said its investigational treatment for Duchenne muscular dystrophy failed to meet its primary and secondary endpoints in a clinical study. The treatment, pamrevlumab, did not achieve the targeted improvement in an ambulatory assessment score at 52 weeks in boys ages six through 11 with ambulatory Duchenne muscular dystrophy, FibroGen said in a release.
- 08/30/2023
|
Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround
- The heavy selling pressure might have exhausted for FibroGen (FGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 08/16/2023
|
FibroGen, Inc. (FGEN) Q2 2023 Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / Investor Relations Enrique Conterno - Chief Executive Officer Thane Wettig - Interim Chief Executive Officer Juan Graham - Chief Financial Officer Chris Chung - Senior Vice President of China Operations Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Annabel Samimy - Stifel Alexandra Ramsey - William Blair Paul Choi - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the FibroGen's Second Quarter 2023 Earnings Call.
- 08/07/2023
|
FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 08/07/2023
|
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
- FibroGen (FGEN) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.78 per share a year ago.
- 08/07/2023
|
FibroGen to Report Second Quarter 2023 Financial Results
- SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 07/24/2023
|
FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- After losing some value lately, a hammer chart pattern has been formed for FibroGen (FGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- 07/14/2023
|
Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround
- The heavy selling pressure might have exhausted for FibroGen (FGEN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
- 07/11/2023
|
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
- FibroGen's lead candidate whiffed twice in June. It has a significant chance of reporting more unfavorable data in Q3.
- 07/01/2023
|
FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study
- FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis fails to meet goals.
- 06/27/2023
|
FibroGen's Unsteady Course: Assessing Fallout From IPF Failure And The Road Ahead
- FibroGen stock has dropped significantly after the failure of its Zephyrus I trial for IPF treatment, leading the company to halt further development in this area. FGEN's future now relies on its pipeline drugs targeting Duchenne muscular dystrophy and pancreatic cancer, both of which are challenging areas with high clinical trial failure rates. Despite a strong financial position and growing sales of Roxadustat in China, the uncertainty surrounding FibroGen's drug pipeline and recent trial failure maintain a "Sell" recommendation for risk-averse investors.
- 06/26/2023
|
Why Is FibroGen (FGEN) Stock Down 81% Today?
- FibroGen (NASDAQ: FGEN ) stock is heading lower on Monday after the company's Phase 3 clinical trial failed to meet its primary endpoint. This was a trial of pamrevlumab as a treatment for patients suffering from IPF.
- 06/26/2023
|
FibroGen to discontinue late-stage trial of treatment for idiopathic pulmonary fibrosis, cut costs to extend cash runway to 2026
- FibroGen Inc. FGEN, -4.06% said Monday it is discontinuing a late-stage trial of a treatment for idiopathic pulmonary fibrosis after it failed to meet its main goal. The San Francisco-based biotech said it would implement a cost-cutting program to extend its cash runway into 2026.
- 06/26/2023
|
FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8%
- FibroGen???s (FGEN) phase III study, evaluating pamrevlumab as a combination therapy in certain DMD patients, fails to meet its primary endpoint.
- 06/08/2023
|
Biotech Stock Falls on Late-Stage Study
- FibroGen Inc (NASDAQ:FGEN) stock is sliding today, after the biotech company announced disappointing results from a late-stage trial of pamrevlumab, its experimental drug to treat patients with Duchenne muscular dystrophy.
- 06/07/2023
|
FibroGen shares slide after Duchenne muscular dystrophy treatment falls short in trial
- Shares of FibroGen Inc. FGEN, -2.50% were down 5.6% premarket on Wednesday after the company announced disappointing results from a late-stage trial of pamrevlumab in non-ambulatory patients with Duchenne muscular dystrophy. The study did not meet the primary endpoint of upper-limb performance after 52 weeks, the company said, although pamrevlumab was generally safe and well tolerated.
- 06/07/2023
|
FibroGen's neuromuscular disorder drug fails in late-stage study
- FibroGen Inc said on Wednesday its drug to treat a type of neuromuscular disorder failed to meet the main goal in a late-stage study, sending the company's shares down about 14% in premarket trading.
- 06/07/2023
|
FibroGen to Present at Jefferies Global Healthcare Conference
- SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following investor conferences:
- 06/06/2023
|
FibroGen: Several Pamrevlumab Data Releases Could Change Scope Of Biotech
- FibroGen, Inc. results from the phase 3 LELANTOS-1 study, using pamrevlumab for the treatment of patients with non-ambulatory Duchenne Muscular Dystrophy, are expected any day now in Q2 of 2023. Results from the phase 3 LELANTOS-2 study, using pamrevlumab for the treatment of patients with ambulatory DMD are expected in Q3 of 2023. It is expected that the global market opportunity for Duchenne Muscular Dystrophy will reach $2.1 billion by 2031.
- 06/05/2023
|
FibroGen, Inc. (FGEN) Q1 2023 Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Michael Tung - Vice President, Corporate Strategy & Investor Relations Enrique Conterno - Chief Executive Officer Juan Graham - Chief Financial Officer Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Conference Call Participants Jason Gerberry - Bank of America Andy Hsieh - William Blair Danielle Brill - Raymond James Paul Choi - Goldman Sachs Michael Yee - Jefferies Annabel Samimy - Stifel Yaron Werber - Cowen Operator Good day, and thank you for standing by. Welcome to FibroGen's First Quarter 2023 Earnings Call.
- 05/08/2023
|
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
- FibroGen (FGEN) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.68 per share a year ago.
- 05/08/2023
|
FibroGen to Report First Quarter 2023 Financial Results
- SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 04/24/2023
|
FibroGen: Despite Some Progress, Roxadustat's Data Disaster Still Haunts It
- FibroGen, Inc. got roxa approved in the EU and China, but not in the U.S. The data manipulation problem from two years ago still haunts FibroGen, Inc.
- 03/29/2023
|
FibroGen, Inc. (FGEN) Q4 2022 Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q4 2022 Earnings Conference Call February 27, 2023 5:00 PM ET Company Participants Michael Tung - VP of Corporate Strategy and IR Enrique Conterno - CEO Mark Eisner - Chief Medical Officer Juan Graham - CFO Thane Wettig - Chief Commercial Officer Conference Call Participants Andrew Tsai - Jefferies Jason Gerberry - Bank of America Andy Hsieh - William Blair Danielle Brill - Raymond James Yaron Werber - Cowen Annabel Samimy - Stifel Operator Thank you for standing by, and welcome to FibroGen's Fourth Quarter and Full Year 2022 Financial Results Earnings Call. [Operator Instructions].
- 02/27/2023
|
FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 02/27/2023
|
FibroGen to Present at Cowen's 43rd Annual Health Care Conference
- SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at Cowen's 43rd Annual Health Care Conference to be held in Boston on March 5 - 8, 2023. Details of the presentations are as follows:
- 02/27/2023
|
Should You Buy FibroGen (FGEN) Ahead of Earnings?
- FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 02/23/2023
|
4 Drug, Biotech Stocks Poised to Beat Q4 Earnings Estimates
- We look at a few drug/biotech companies, TBPH, FGEN, AUPH, CYTK, which are poised to beat on earnings in the fourth quarter.
- 02/23/2023
|
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
- SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
- 02/17/2023
|
GSK's Daprodustat Drug for Anemia Due to CKD Gets FDA Nod
- GSK announces the FDA approval of daprodustat for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least four months.
- 02/02/2023
|
FibroGen to Present at SVB Securities Global Biopharma Conference
- SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Thursday, February 16 at 3:40 PM Eastern Time.
- 02/02/2023
|
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
- SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8, at 1:05 PM Eastern Time.
- 11/28/2022
|
FibroGen, Inc. (FGEN) Q3 2022 Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q3 2022 Earnings Conference Call November 7, 2022 5:00 PM ET Company Participants Michael Tung - IR Executive Enrique Conterno - CEO & Director Juan Graham - CFO Mark Eisner - EVP & Chief Medical Officer Thane Wettig - EVP & Chief Commercial Officer Christine Chung - SVP, China Operations Conference Call Participants Jason Gerberry - Bank of America Merrill Lynch Jack Padovano - Stifel, Nicolaus & Company Michael Yee - Jefferies Alexander Nackenoff - Raymond James & Associates Andy Hsieh - William Blair & Company Yaron Werber - Cowen Paul Choi - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to FibroGen's Third Quarter 2022 Earnings Call.
- 11/07/2022
|
FibroGen to Report Third Quarter 2022 Financial Results
- SAN FRANCISCO, Oct. 24, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2022 financial results on Monday, November 7 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
- 10/24/2022
|
7 Unknown Biotech Stocks That Could Rocket in 2023
- Investing in early-stage or unknown biotech stocks can be likened to investing in cryptocurrency projects. If the project developments are positive, returns can be multi-folds in a short time.
- 09/23/2022
|
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q2 2022 Results - Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Michael Tung - Corporate Strategy and IR Enrique Conterno - CEO Mark Eisner - Chief Medical Officer Juan Graham - CFO Thane Wettig - Chief Commercial Officer Chris Chung - Senior Vice President of China Operations Conference Call Participants Michael Yee - Jefferies Annabel Samimy - Stifel Andy Hsieh - William Blair Brendan Smith - Cowen Paul Choi - Goldman Sachs Jason Gerberry - Bank of America Operator Good day and thank you for standing by. Welcome to the FibroGen 's Second Quarter 2022 Earnings Call.
- 08/08/2022
|
FibroGen (FGEN) Reports Q2 Loss, Misses Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of 17.02% and 18.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/08/2022
|
FibroGen to Report Second Quarter 2022 Financial Results
- SAN FRANCISCO, July 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2022 financial results on Monday, August 8 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
- 07/25/2022
|
FibroGen to Present at Jefferies Healthcare Conference
- SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT.
- 05/26/2022
|
What Stocks To Buy This Week? 4 Biotech Stocks To Know
- Should investors pay more attention to these biotech stocks?
- 05/15/2022
|
FibroGen, Inc.'s (FGEN) CEO Enrique Conterno on Q1 2022 Results - Earnings Call Transcript
- FibroGen, Inc. (NASDAQ:FGEN ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Michael Tung – Corporate Strategy/Investor Relations Enrique Conterno – Chief Executive Officer Mark Eisner – Chief Medical Officer Juan Graham – Chief Financial Officer Thane Wettig – Chief Commercial Officer Chris Chung – Senior Vice President of China Operations Conference Call Participants Michael Yee – Jefferies Andy Hsieh – William Blair Yaron Werber – Cowen Annabel Samimy – Stifel Operator Ladies and gentlemen, thank you for standing by and welcome to the FibroGen's First Quarter 2022 Earnings Conference Call. At this time all participants' lines are in a listen-only mode.
- 05/09/2022
|
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of 19.05% and 120.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/09/2022
|
FibroGen (FGEN) Expected to Beat Earnings Estimates: Should You Buy?
- FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 05/02/2022
|
FibroGen to Report First Quarter 2022 Financial Results
- SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
- 04/25/2022
|
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q4 2021 Results - Earnings Call Transcript
- FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q4 2021 Results - Earnings Call Transcript
- 02/28/2022
|
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of -113.24% and 62.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/28/2022
|
FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results
- SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
- 02/14/2022
|
FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference
- SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST.
- 02/04/2022
|
FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference
- SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13. The on-demand webcast of the session will be available on January 10 at 7:00am EST.
- 01/04/2022
|
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2021 Earnings Call Transcript
- FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2021 Earnings Call Transcript
- 11/09/2021
|
FibroGen (FGEN) Q3 Earnings and Revenues Surpass Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of 500.00% and 15.25%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/09/2021
|
FibroGen to Present at Upcoming Investor Conferences
- SAN FRANCISCO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the following healthcare conferences:
- 11/02/2021
|
FibroGen to Report Third Quarter 2021 Financial Results
- SAN FRANCISCO, Oct. 26, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2021 financial results on Tuesday, November 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
- 10/26/2021
|
What's Happening With FibroGen Stock?
- Last month, we discussed that FibroGen (NASDAQ: FGEN) stock price could rebound over a one-month period after falling 6% in a week, based on the Trefis Machine Learning Engine. However, FGEN stock has seen a decline of over 12% since then, and it is down 5% in the last five trading days.
- 10/04/2021
|
Why FibroGen Fell by More Than 9% on Wednesday
- A noted investment bank takes a dimmer view of the company's stock.
- 09/22/2021
|
Will FibroGen Stock Rebound After Positive Roxadustat Data?
- The stock price of FibroGen, a biopharmaceutical company focused on therapeutics in immunology and oncology, reached its 52-week high of $56 in February this year before a large sell-off in FGEN stock, especially after the company disclosed that safety analyses from a late-stage study of Roxadustat.
- 09/01/2021
|
FibroGen (FGEN) Meets Main Goal in Chemo-Induced Anemia Study
- FibroGen (FGEN) announces positive top-line data from the study of its investigational candidate roxadustat, which is being evaluated to treat chemotherapy-induced anemia.
- 08/26/2021
|
FibroGen's Roxadustat Aces Chemo-Induced Anemia Trial
- FibroGen Inc (NASDAQ: FGEN) has announced topline data from WHITNEY Phase 2 study of roxadustat for chemotherapy-induced anemia (CIA). The trial met the primary efficacy endpoint of maximum change in hemoglobin within 16 weeks from baseline without red blood cell transfusion.
- 08/25/2021
|
FibroGen Announces Positive Topline Results from Phase 2 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia
- SAN FRANCISCO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive topline results from WHITNEY, the Company's Phase 2 clinical study of roxadustat, a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of chemotherapy-induced anemia (CIA).
- 08/25/2021
|
After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat
- The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by chronic kidney disease (CKD), just days after the FDA turned down the drug. Related: FDA Shoots Down Roxadustat Application, Asks For Additional Trial.
- 08/20/2021
|
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
- Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl hydroxylase (PH) inhibitor available for adult patients with anemia associated with chronic kidney disease in Europe
- 08/19/2021
|
3 Beaten Down Stocks that Could be Ready to Bounce
- Photo credit sergeitokmakov @ Pixabay Trading against the trend can be a very difficult way to generate returns in the market, yet there usually comes a time when a stock in a downtrend simply runs out of sellers.
- 08/17/2021
|
FibroGen Announces Retirement of Pat Cotroneo and Appointment of Juan Graham as Chief Financial Officer
- SAN FRANCISCO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the retirement of Pat Cotroneo, Chief Financial Officer, and the appointment of Juan Graham in that role. Pat will continue as Chief Financial Officer through September 6, 2021, and will remain with FibroGen through March 31, 2022 serving as Executive Advisor to the CEO to ensure a smooth transition.
- 08/16/2021
|
FibroGen's (FGEN) Drug for Anemia of CKD Gets CRL From FDA
- NDA for roxadustat, FibroGen's (FGEN) candidate for anemia of chronic kidney disease, fails to secure approval as the FDA requests additional clinical data on the drug. The stock declines resultantly.
- 08/12/2021
|
FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial
- The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc's (NASDAQ: FGEN) roxadustat for anemia of chronic kidney disease (CKD). The letter indicates the FDA will not approve the roxadustat NDA in its present form and has requested an additional clinical study of roxadustat be conducted.
- 08/11/2021
|
FibroGen Receives Complete Response Letter from the FDA for Roxadustat for Anemia of Chronic Kidney Disease
- SAN FRANCISCO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD).
- 08/11/2021
|
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q2 2021 Results - Earnings Call Transcript
- FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q2 2021 Results - Earnings Call Transcript
- 08/09/2021
|
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of -202.08% and -68.93%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/09/2021
|
Why FibroGen (FGEN) Might Surprise This Earnings Season
- FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 08/05/2021
|
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
- FDA approval of roxadustat seems unlikely.
- 07/29/2021
|
Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology and Recombinant Collagen III Platform
- SUZHOU, China and SAN FRANCISCO, July 19, 2021 (GLOBE NEWSWIRE) -- Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, announced today that it has exclusively licensed global rights for the development and commercialization of an investigational biosynthetic cornea derived from recombinant human collagen Type III intended to treat patients with corneal blindness, from FibroGen, Inc. (FibroGen; NASDAQ: FGEN).
- 07/19/2021
|
Here's Why FibroGen Stock Is Plunging Today
- An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns.
- 07/16/2021
|
FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall
- FibroGen (FGEN) stock is falling hard on Friday after the company received the results of an FDA review for one of its drugs. The post FGEN Stock: The Huge FDA News Causing FibroGen Shares to Free Fall appeared first on InvestorPlace.
- 07/16/2021
|
FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote
- FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.
- 07/16/2021
|
Why FibroGen's Stock Is Getting Hammered Today
- FibroGen, Inc. (NASDAQ: FGEN) shares are trading lower after an FDA Advisory Committee panel voted against approval of the company's New Drug Application for roxadustat to treat anemia due to chronic kidney disease in adult patients. 'While we are disappointed with today's outcome,' said CEO Enrique Conterno, 'we believe the scientific evidence supports roxadustat approval in the U.S. and will work with the FDA as it completes its review of the New Drug Application for roxadustat.
- 07/16/2021
|
AstraZeneca says FDA advisory committee won't support CKD treatment for approval, partner FibroGen stock plunges
- AstraZeneca PLC has disclosed Friday that a U.S. Food and Drug Administration advisory committee has voted 13 to 1 not to support approval of roxadustat for the treatment of anaemia in chronic kidney disease (CKD) in non-dialysis dependent adult patients. Shares of FibroGen Inc. , which was AstraZeneca's partner in developing roxadustat, plummeted 34.1% in premarket trading, while AstraZeneca's U.S.-listed shares edged up 0.4%.
- 07/16/2021
|
FibroGen Staring At Multi-Year Lows Following Adverse Roxadustat AdCom Verdict; How Hard Will The Stock Likely Fall?
- FibroGen, Inc.'s (NASDAQ: FGEN) shares are sinking to their lowest level since late June 2016. FibroGen's AdCom Snub FibroGen said late Thursday the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee met to discuss the new drug application for roxadustat, voted against approval of the drug.
- 07/16/2021
|
FibroGen Stock Craters After Roxadustat Setback, But There Is A Silver Lining
- Yesterday, the U.S. FDA voted not to approve Roxadustat for the treatment of anemia due to chronic kidney disease in adult patients.
- 07/16/2021
|
AstraZeneca and FibroGen face FDA rejection of anaemia drug
- AstraZeneca PLC (LON:AZN) faces rejection from the US drug regulator for its application for a novel new drug to treat anaemia resulting from chronic kidney disease (CKD). The Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee voted against approving Roxadustat on the basis of its benefit-risk profile for both non-dialysis dependent and dialysis-dependent adult patients.
- 07/16/2021
|
AstraZeneca and FibroGen face FDA red light over anaemia drug
- AstraZeneca PLC (LON:AZN) is facing rejection from the US drug regulator for its application for a novel new drug to treat anaemia resulting from chronic kidney disease. The Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee voted against approving Roxadustat on the basis of its benefit-risk profile for both non-dialysis dependent and dialysis-dependent adult patients.
- 07/16/2021
|
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease
- SAN FRANCISCO, July 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients. The Committee based its recommendation on data from a global Phase 3 program encompassing more than 8,000 patients. While the FDA is not required to follow the Committee's vote, the agency considers the Committee's non-binding recommendations when making its decision.
- 07/15/2021
|
What 3 FibroGen Analysts Are Expecting From Thursday's Roxadustat Adcom Verdict
- FibroGen, Inc. (NASDAQ:FGEN) has a key catalyst Thursday when FDA's Cardiovascular and Renal Drugs Advisory Committee will issue its recommendation on the company's new drug application for roxadustat. The committee is scheduled to meet between 9:30 a.m.
- 07/14/2021
|
Ahead Of AdComm AstraZeneca, FibroGen's Roxadustat Hit With Safety, Efficacy Questions
- Ahead of Thursday's meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee, the agency is raising fresh doubts on the safety of AstraZeneca Plc's (NASDAQ: AZN) and FibroGen Inc's (NASDAQ: FGEN) anemia drug roxadustat. FDA staffers flagged concerning evidence of blood clotting, when compared with placebo in nondialysis-dependent patients but also when compared against Amgen Inc (NASDAQ: AMGN) and Johnson & Johnson's (NYSE: JNJ) Epogen/Procrit, "which is itself known to pose these risks," in dialysis-dependent patients.
- 07/13/2021
|
FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer
- SAN FRANCISCO, July 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen's research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience.
- 07/12/2021
|
European Regulators Suggest Approval of FibroGen's Key Drug
- European regulators issued a positive recommendation on FibroGen's key drug roxadustat, which has had major setbacks in its path to approval in the U.S.
- 06/25/2021
|
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
- TOKYO, June 25, 2021 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).1 CKD impacts one in 10 people globally, of whom one in five are affected by anemia.2, 3 Anemia of CKD is associated with significant impairment in quality of life and progression to adverse cardiovascular (CV) and renal outcomes.4-6 Anemia of CKD is often untreated or not treated to target.4-6
- 06/25/2021
|
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease
- SAN FRANCISCO and CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherapeutics company with expertise in immune modulation and single cell science announced a partnership covering three HiFiBiO programs.
- 06/17/2021
|
Pamrevlumab Included in Pancreatic Cancer Action Network's Adaptive Clinical Trial Platform
- SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise SM adaptive trial platform evaluating pamrevlumab [and standard of care] for patients with metastatic pancreatic cancer. The objective of Precision Promise is to expedite the study and approval of promising therapies for pancreatic cancer by bringing multiple stakeholders together, including academic, industry and regulatory entities.
- 06/16/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or...
- 06/12/2021
|
DEADLINE TODAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 06/11/2021
|
Final Day to Actively Participate: FibroGen, Inc. (FGEN) Class Action - Bronstein, Gewirtz & Grossman, LLC
- New York, New York--(Newsfile Corp. - June 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired FibroGen securities between December 20, 2018 and April 6, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...
- 06/11/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- NEW YORK, June 10, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021 (the "Class Period"), seeking to recover damages pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), 15 U.S.C.
- 06/10/2021
|
FibroGen Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 10, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 06/10/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 10, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 06/10/2021
|
FINAL DEADLINE TOMORROW: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
- LOS ANGELES, June 10, 2021 /PRNewswire/ -- The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6, 2021, inclusive (the "Class Period").
- 06/10/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - June 10, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 06/10/2021
|
DEADLINE TOMORROW: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 10, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 06/10/2021
|
Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for FibroGen, Inc. Investors - FGEN
- Radnor, Pennsylvania--(Newsfile Corp. - June 10, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired FibroGen securities and/or sold...
- 06/10/2021
|
FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of FibroGen, Inc. Shareholders
- New York, New York--(Newsfile Corp. - June 9, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders FibroGen, Inc. (NASDAQ: FGEN).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=16752&from=5
- 06/09/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - (FGEN)
- New York, New York--(Newsfile Corp. - June 9, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN).Shareholders who purchased shares of FGEN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=16748&from=5
- 06/09/2021
|
FGEN FINAL DEADLINE FRIDAY: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN
- NEW YORK, June 9, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"), of the important June 11, 2021 lead plaintiff deadline. SO WHAT: If you purchased FibroGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 06/09/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - June 9, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16739&wire=5
- 06/09/2021
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
- 06/09/2021
|
FRIDAY DEADLINE NOTICE: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 9, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 06/09/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 9, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 06/09/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - June 8, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 06/08/2021
|
FibroGen Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 8, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between November...
- 06/08/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - June 8, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16688&wire=5
- 06/08/2021
|
FRIDAY DEADLINE REMINDER: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - June 8, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 06/08/2021
|
JUNE 11 2021 FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
- New York, New York--(Newsfile Corp. - June 8, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fibrogen, Inc., ("Fibrogen" or the "Company") (NASDAQ: FGEN) from November 8, 2019, through April 6, 2021 (the "Class Period"). The lawsuit filed in the...
- 06/08/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 7, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 06/07/2021
|
FibroGen Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 6, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 06/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- New York, New York--(Newsfile Corp. - June 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or...
- 06/05/2021
|
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - June 5, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired FibroGen securities during...
- 06/05/2021
|
FibroGen Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 5, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between November...
- 06/05/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 4, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 06/04/2021
|
JUNE 11 2021 FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
- New York, New York--(Newsfile Corp. - June 3, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fibrogen, Inc., ("Fibrogen" or the "Company") (NASDAQ: FGEN) from November 8, 2019, through April 6, 2021 (the "Class Period"). The lawsuit filed in the...
- 06/03/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - June 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 06/03/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 06/03/2021
|
ROSEN, LEADING INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors With Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN
- New York, New York--(Newsfile Corp. - June 2, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"), of the important June 11, 2021 lead plaintiff deadline.SO WHAT: If you purchased FibroGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 06/02/2021
|
FibroGen Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - June 2, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between November...
- 06/02/2021
|
FGEN Investor Reminder: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Against FibroGen, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - June 2, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline: June 11, 2021Website: https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogenContact: James Maro, Esq. (484)...
- 06/02/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - June 2, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 06/02/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - (FGEN)
- New York, New York--(Newsfile Corp. - June 2, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN).Shareholders who purchased shares of FGEN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:
- 06/02/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - June 1, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 06/01/2021
|
Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
- RADNOR, Pa., June 1, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021 , inclusive (the "Class Period").
- 06/01/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - June 1, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16436&wire=5
- 06/01/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - June 1, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 06/01/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- NEW YORK, June 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021 (the "Class Period"), seeking to recover damages pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), 15 U.S.C.
- 06/01/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 31, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/31/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 31, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information go to:https://www.zlk.com/pslra-1/fibrogen-inc-information-request-form?prid=16356&wire=5or...
- 05/31/2021
|
Fibrogen Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 30, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between November...
- 05/30/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- New York, New York--(Newsfile Corp. - May 29, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or...
- 05/29/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages FibroGen, Inc. Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN
- NEW YORK, May 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"), of the important June 11, 2021 lead plaintiff deadline. SO WHAT: If you purchased FibroGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/29/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of FibroGen, Inc. of Deadline in Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - May 29, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired FibroGen securities during the...
- 05/29/2021
|
FibroGen Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 29, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between November...
- 05/29/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
- LOS ANGELES, May 28, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) securities between October 18, 2017 and April 6, 2021 , inclusive (the "Class Period"). If you suffered a loss on your FibroGen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/fibrogen-inc/.
- 05/28/2021
|
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Fibrogen, Inc. - FGEN
- New Orleans, Louisiana--(Newsfile Corp. - May 28, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NASDAQ: FGEN), if they purchased the Company's securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"). These...
- 05/28/2021
|
FibroGen Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 27, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between November...
- 05/27/2021
|
FibroGen to Present at Upcoming Investor Conferences
- SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:
- 05/27/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 27, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc..Shareholders who purchased shares of FGEN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:
- 05/27/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - May 26, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16252&wire=5
- 05/26/2021
|
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)
- RADNOR, Pa., May 26, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021 , inclusive (the "Class Period").
- 05/26/2021
|
FIBROGEN INVESTOR ALERT: Shareholder Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - May 26, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of FibroGen, Inc. (NASDAQ: FGEN). The case is currently in the lead plaintiff stage. Investors who purchased FGEN stock or other securities between November 8, 2019 and April 6, 2021, may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/FibroGen for more information. Investors may also email...
- 05/26/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/26/2021
|
FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of FibroGen, Inc. Shareholders
- New York, New York--(Newsfile Corp. - May 25, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders FibroGen, Inc. (NASDAQ: FGEN).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=16196&from=5
- 05/25/2021
|
FibroGen Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 25, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 05/25/2021
|
FGEN DEADLINE REMINDER: Kessler Topaz Meltzer & Check, LLP - Important June 11, 2021 Deadline Reminder for FibroGen, Inc. Investors
- Radnor, Pennsylvania--(Newsfile Corp. - May 25, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline: June 11, 2021Website: https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogenContact: James Maro, Esq. (484)...
- 05/25/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - May 25, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16164&wire=5
- 05/25/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 25, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/25/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- NEW YORK, May 25, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021 (the "Class Period"), seeking to recover damages pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), 15 U.S.C.
- 05/25/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 24, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/24/2021
|
HAGENS BERMAN Encourages FibroGen (FGEN) Investors with Losses to Contact the Firm, Deadline Approaching in Securities Fraud Class Action
- San Francisco, California--(Newsfile Corp. - May 24, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 - Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGEN Contact An Attorney Now: FGEN@hbsslaw.com 844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen's presentation of false data of roxadustat to make the...
- 05/24/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 24, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/24/2021
|
FibroGen News: Berger Montague Investigates Securities Fraud Allegations Against FibroGen, Inc. (FGEN); Lead Plaintiff Deadline is June 11, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - May 23, 2021) - Berger Montague is investigating potential securities fraud claims against FibroGen, Inc. ("FibroGen" or the "Company"). The Firm is investigating these claims on behalf of FibroGen investors who purchased securities (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021 (the "Class Period"). If you purchased FibroGen securities, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz...
- 05/23/2021
|
FibroGen Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 23, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 05/23/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- New York, New York--(Newsfile Corp. - May 22, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or...
- 05/22/2021
|
FibroGen Stock: Berger Montague Investigates Potential Securities Fraud Claims Against FibroGen, Inc. (FGEN); Lead Plaintiff Deadline is June 11, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2021) - Berger Montague is investigating potential securities fraud claims against FibroGen, Inc. ("FibroGen" or the "Company"). The Firm is investigating these claims on behalf of FibroGen investors who purchased securities (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021 (the "Class Period"). If you purchased FibroGen securities, would like to discuss Berger Montague's investigation, or have questions concerning your rights or interests, please contact attorneys Andrew Abramowitz...
- 05/22/2021
|
FibroGen Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 22, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 05/22/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - May 21, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16065&wire=5
- 05/21/2021
|
Rosen, Trusted Investor Counsel, Encourages FibroGen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FGEN
- New York, New York--(Newsfile Corp. - May 21, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"), of the important June 11, 2021 lead plaintiff deadline.SO WHAT: If you purchased FibroGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 05/21/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/21/2021
|
FGEN Stock: Berger Montague Investigates Potential Securities Fraud Claims Against FibroGen, Inc. (FGEN); Lead Plaintiff Deadline is June 11, 2021
- Philadelphia, Pennsylvania--(Newsfile Corp. - May 21, 2021) - Berger Montague is investigating potential securities fraud claims against FibroGen, Inc. ("FibroGen" or the "Company") on behalf of investors who purchased FibroGen securities (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021 (the "Class Period"). If you purchased FibroGen securities, have questions concerning your rights or interests, or would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or...
- 05/21/2021
|
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN
- New Orleans, Louisiana--(Newsfile Corp. - May 20, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NasdaqGS: FGEN), if they purchased the Company's securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"). These...
- 05/20/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 20, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/20/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Filed Against FibroGen, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - May 20, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline: June 11, 2021Website: https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogen Contact: James Maro,...
- 05/20/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
- LOS ANGELES, May 20, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired FibroGen Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) securities and/or sold put options between October 18, 2017 and April 6, 2021 inclusive (the "Class Period").
- 05/20/2021
|
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against FibroGen, Inc. – FGEN and June 11 Deadline
- NEW YORK--(BUSINESS WIRE)-- #FGEN--INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against FibroGen, Inc. – FGEN and June 11 Deadline
- 05/20/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 19, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/19/2021
|
FibroGen Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsVancouver, British Columbia--(Newsfile Corp. - May 19, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between November 8,...
- 05/19/2021
|
ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors With Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN
- New York, New York--(Newsfile Corp. - May 18, 2021) - WHY: New York, N.Y., May 18, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"), of the important June 11, 2021 lead plaintiff deadline.SO WHAT: If you purchased FibroGen securities during the Class Period you may be entitled to compensation without payment...
- 05/18/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 18, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 05/18/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- NEW YORK, May 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021 (the "Class Period"), seeking to recover damages pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), 15 U.S.C.
- 05/18/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact the Firm to Recover Losses Due to Alleged Securities Fraud
- San Francisco, California--(Newsfile Corp. - May 17, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 - Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGENContact An Attorney Now: FGEN@hbsslaw.com844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.Throughout the Cla
- 05/17/2021
|
FibroGen's Cardiovascular Data Mess
- FibroGen's NDA was being delayed by the FDA, and the company was thought to be a victim.
- 05/17/2021
|
FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
- NEW YORK, May 17, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fibrogen, Inc., ("Fibrogen" or the "Company") (NASDAQ: FGEN) from November 8, 2019, through April 6, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.
- 05/17/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 17, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 05/17/2021
|
Investor Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN) - Expanded Class Period
- Radnor, Pennsylvania--(Newsfile Corp. - May 17, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that securities fraud class action lawsuits have been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder:...
- 05/17/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/16/2021
|
FGEN ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - Expanded Class Period
- RADNOR, Pa., May 16, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that securities fraud class action lawsuits have been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021 , inclusive (the "Class Period").
- 05/16/2021
|
FibroGen Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 05/14/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Against FibroGen, Inc. - Expanded Class Period
- Radnor, Pennsylvania--(Newsfile Corp. - May 14, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that securities fraud class action lawsuits have been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from October 18, 2017 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder:...
- 05/14/2021
|
FIBROGEN INVESTOR ALERT: June 11, 2021 Deadline for Seeking Appointment as Lead Plaintiff In Securities Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)
- San Francisco, California--(Newsfile Corp. - May 14, 2021) - On April 12, 2021, Berman Tabacco's California office filed a class action lawsuit for violations of the federal securities laws against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN), and certain of its current and former officers and directors, on behalf of all other persons and entities who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April...
- 05/14/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 14, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc..Shareholders who purchased shares of FGEN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=15896&from=5CLASS PERIOD : October 18, 2017 to April 6, 2021ALLEGAT
- 05/14/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - May 14, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=15878&wire=5
- 05/14/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/14/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 14, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 05/14/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/14/2021
|
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN
- New Orleans, Louisiana--(Newsfile Corp. - May 13, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NASDAQ: FGEN), if they purchased the Company's securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"). These...
- 05/13/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.
- Los Angeles, California--(Newsfile Corp. - May 13, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 05/13/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 13, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/13/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- NEW YORK, May 13, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021 (the "Class Period"), seeking to recover damages pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), 15 U.S.C.
- 05/13/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 12, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/12/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - May 12, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=15766&wire=5
- 05/12/2021
|
FGEN CLASS ACTION ALERT: Hagens Berman, National Trial Attorneys, Recommends FibroGen (FGEN) Investors with Losses to Contact the Firm
- San Francisco, California--(Newsfile Corp. - May 12, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now.Class Period: Oct. 18, 2017 - Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGENContact An Attorney Now: FGEN@hbsslaw.com844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.Throughout the Clas
- 05/12/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.
- Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers, which expands the class period. The class action is on behalf of a class consisting of investors who purchased or otherwise acquired FibroGen securities between October 18, 2017 and April 6,...
- 05/12/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 11, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: October 18, 2017 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/11/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 11, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/11/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
- BENSALEM, Pa., May 11, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 05/11/2021
|
HAGENS BERMAN Alerts FibroGen (FGEN) Investors to EXPANDED FRAUDULENT PERIOD in Securities Fraud Action: Investors Should Secure Counsel
- SAN FRANCISCO, May 11, 2021 /PRNewswire/ -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. Class Period: Oct. 18, 2017 – Apr. 6, 2021 Lead Plaintiff Deadline: June 11, 2021 Visit: www.hbsslaw.com/cases/FGEN Contact An Attorney Now: FGEN@hbsslaw.com 844-916-0895 FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.
- 05/11/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.
- 05/11/2021
|
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q1 2021 Results - Earnings Call Transcript
- FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q1 2021 Results - Earnings Call Transcript
- 05/10/2021
|
ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages FibroGen, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - FGEN
- NEW YORK, May 10, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"), of the important June 11, 2021 lead plaintiff deadline. SO WHAT: If you purchased FibroGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 05/10/2021
|
FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of 13.33% and 1.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/10/2021
|
FibroGen Reports First Quarter 2021 Financial Results
- SAN FRANCISCO, May 10, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2021 and provided an update on the Company's recent developments.
- 05/10/2021
|
FGEN INVESTORS WHO LOST MONEY; HAGENS BERMAN, National Trial Attorneys, Alerts FibroGen (FGEN) Investors to Securities Class Action, Encourages Investors with Losses to Contact the Firm Now
- San Francisco, California--(Newsfile Corp. - May 10, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now.Class Period: Oct. 18, 2017 - Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGENContact An Attorney Now: FGEN@hbsslaw.com844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.
- 05/10/2021
|
The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc.
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc.
- 05/10/2021
|
Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder for FibroGen, Inc. Investors - Expanded Class Period
- RADNOR, Pa., May 10, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from December 20, 2018 through April 6, 2021 , inclusive (the "Class Period").
- 05/10/2021
|
FIBROGEN INVESTOR ALERT: Class Action Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - May 8, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of FibroGen, Inc. (NASDAQ: FGEN). The case is currently in the lead plaintiff stage. Investors who purchased FGEN stock or other securities between November 8, 2019 and April 6, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/FibroGen for more information. Investors may also email...
- 05/08/2021
|
Berman Tabacco Announces June 11, 2021 Deadline For Lead Plaintiff Motions In Its Securities Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN) In the Northern District of California
- San Francisco, California--(Newsfile Corp. - May 7, 2021) - On April 12, 2021, Berman Tabacco filed a class action lawsuit for violations of the federal securities laws against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN), and certain of its current and former officers and directors, on behalf of all other persons and entities who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021...
- 05/07/2021
|
Why Earnings Season Could Be Great for FibroGen (FGEN)
- FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/07/2021
|
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Fibrogen, Inc. - FGEN
- New Orleans, Louisiana--(Newsfile Corp. - May 6, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11, 2021 to file lead plaintiff applications in securities class action lawsuits against FibroGen, Inc. (NASDAQ: FGEN), if they purchased the Company's securities and/or sold put options between October 18, 2017 and April 6, 2021, inclusive (the "Class Period"). These...
- 05/06/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 6, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 05/06/2021
|
Important Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Investors of Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - May 6, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired FibroGen securities during the...
- 05/06/2021
|
ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors With Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN
- New York, New York--(Newsfile Corp. - May 5, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021, inclusive (the "Class Period"), of the important June 11, 2021 lead plaintiff deadline.SO WHAT: If you purchased FibroGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...
- 05/05/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - May 5, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=15517&wire=5
- 05/05/2021
|
FGEN Reminder: Kessler Topaz Meltzer & Check, LLP - Deadline Reminder for FibroGen, Inc. Investors
- RADNOR, Pa., May 5, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021 , inclusive (the "Class Period").
- 05/05/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/05/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN
- New York, New York--(Newsfile Corp. - May 5, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or...
- 05/05/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
- LOS ANGELES, May 5, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) securities between November 8, 2019 and April 6, 2021 , inclusive (the "Class Period"). If you suffered a loss on your FibroGen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/fibrogen-inc/.
- 05/05/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 5, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 05/05/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 5, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/05/2021
|
Fibrogen Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 4, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 05/04/2021
|
CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces Class Action Lawsuit Has Been Filed Against FibroGen, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - May 4, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline: June 11, 2021Website: https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogenContact: James Maro, Esq. (484)...
- 05/04/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/04/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 4, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 05/04/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - May 3, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=15437&wire=5
- 05/03/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - May 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 05/03/2021
|
LAWSUIT FILED: FibroGen, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton
- Boston, Massachusetts--(Newsfile Corp. - May 3, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that a lawsuit for violations of the federal securities laws has been filed against FibroGen, Inc. (NASDAQ: FGEN) and certain of its executives. Investors should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600. The deadline to move for appointment as lead plaintiff is...
- 05/03/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - May 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 05/03/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - May 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 05/03/2021
|
Pomerantz Law Firm Announces the Filing of a Class Action Against FibroGen, Inc. and Certain Officers - FGEN
- NEW YORK, May 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021 (the "Class Period"), seeking to recover damages pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act"), 15 U.S.C.
- 05/01/2021
|
FibroGen Update
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - May 1, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 05/01/2021
|
Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit
- RADNOR, Pa., April 30, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021 , inclusive (the "Class Period").
- 04/30/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 04/30/2021
|
Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for
- FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/29/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 29, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more...
- 04/29/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen" or "the Company") for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the ''Class Period''),...
- 04/29/2021
|
FibroGen Stock: Berger Montague Investigates Potential Securities Fraud Claims Against FibroGen, Inc. (FGEN) For Manipulating Drug Data
- Philadelphia, Pennsylvania--(Newsfile Corp. - April 29, 2021) - Berger Montague is investigating potential securities fraud claims against FibroGen, Inc. ("FibroGen" or the "Company") on behalf of investors who purchased FibroGen securities (NASDAQ: FGEN). If you purchased FibroGen securities, have questions concerning your rights or interests, or would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Donnell Much at dmuch@bm.net or (215) 875-4667, or contact us at...
- 04/29/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether FibroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...
- 04/28/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds FibroGen, Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit
- Radnor, Pennsylvania--(Newsfile Corp. - April 28, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired FibroGen securities during the...
- 04/28/2021
|
FGEN INVESTOR ALERT: Class Action Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - April 28, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of FibroGen, Inc. (NASDAQ: FGEN). The case is currently in the lead plaintiff stage. Investors who purchased FGEN stock or other securities between November 8, 2019 and April 6, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/FibroGen to submit their information. Investors may also...
- 04/28/2021
|
FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Fibrogen, Inc. Shareholders
- New York, New York--(Newsfile Corp. - April 28, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders FibroGen, Inc. (NASDAQ: FGEN).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=15252&from=5
- 04/28/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 28, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 04/28/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - April 28, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=15236&wire=5
- 04/28/2021
|
LAWSUIT FILED: FibroGen, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton
- Boston, Massachusetts--(Newsfile Corp. - April 28, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that a lawsuit for violations of the federal securities laws has been filed against FibroGen, Inc. (NASDAQ: FGEN) and certain of its executives. Investors should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600. The deadline to move for appointment as lead plaintiff is...
- 04/28/2021
|
FibroGen to Present at Upcoming Investor Conference
- SAN FRANCISCO, April 28, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 13, 2021 at 5:00 PM Eastern Time.
- 04/28/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 28, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 04/28/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 27, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 04/27/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 04/27/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - April 27, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=15176&wire=5
- 04/27/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- NEW YORK, April 26, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are advised to contact Robert S.
- 04/26/2021
|
ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN
- NEW YORK, April 26, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021, inclusive (the "Class Period"), of the important June 11, 2021 lead plaintiff deadline. SO WHAT: If you purchased FibroGen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/26/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 26, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 04/26/2021
|
FIBROGEN INVESTORS: June 11, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
- SAN FRANCISCO--(BUSINESS WIRE)-- #FGEN--FIBROGEN INVESTORS: June 11, 2021 Filing Deadline in Class Action – Contact Lieff Cabraser
- 04/26/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 26, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more...
- 04/26/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 26, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 04/26/2021
|
FibroGen Class Action Reminder
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 25, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ:FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between November...
- 04/25/2021
|
Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. (FGEN)
- RADNOR, Pa., April 24, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021 , inclusive (the "Class Period").
- 04/24/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 23, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 04/23/2021
|
Kessler Topaz Meltzer & Check, LLP: Reminds Investors of Securities Fraud Class Action Filed Against FibroGen, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - April 23, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") that a securities fraud class action lawsuit has been filed against on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Lead Plaintiff Deadline: June 11, 2021Website: https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogen Contact: James Maro,...
- 04/23/2021
|
Fibrogen Shareholder Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 23, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and reminds investors of the June 11, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $50,000 investing in FibroGen stock or options between...
- 04/23/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed, Investor Deadline Established
- San Francisco, California--(Newsfile Corp. - April 23, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now.Class Period: Nov. 8, 2019 - Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGENContact An Attorney Now: FGEN@hbsslaw.com844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.Throughout the Cl
- 04/23/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 04/23/2021
|
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN
- New Orleans, Louisiana--(Newsfile Corp. - April 22, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11, 2021 to file lead plaintiff applications in a securities class action lawsuit against FibroGen, Inc. (NASDAQ: FGEN), if they purchased the Company's securities and/or sold put options between November 8, 2019 and April 6, 2021, inclusive (the "Class Period"). ...
- 04/22/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 22, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 04/22/2021
|
Fibrogen Investor Alert: Class Action Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - April 22, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of FibroGen, Inc. (NASDAQ: FGEN). The case is currently in the lead plaintiff stage. Investors who purchased FGEN stock or other securities between November 8, 2019 and April 6, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/FibroGen to submit their information. Investors may also email...
- 04/22/2021
|
INVESTOR ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 22, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 04/22/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether FibroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 04/21/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Securities Fraud Class Action Filed and Important Deadline Established
- San Francisco, California--(Newsfile Corp. - April 21, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now.Class Period: Nov. 8, 2019 - Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGENContact An Attorney Now: FGEN@hbsslaw.com844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.Throughout the Cla
- 04/21/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)
- BENSALEM, Pa.--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) securities between November 8, 2019 and April 6, 2021, inclusive (the “Class Period”). Investors suffering losses on their FibroGen investments are encouraged to contact the Law Offices of Howard G. Smit
- 04/21/2021
|
INVESTOR ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 04/21/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more...
- 04/21/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
- Radnor, Pennsylvania--(Newsfile Corp. - April 20, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Investor Deadline Reminder: Investors who purchased or acquired FibroGen securities during the...
- 04/20/2021
|
FIBROGEN INVESTOR ALERT: Shareholder Lawsuit Filed
- Boston, Massachusetts--(Newsfile Corp. - April 20, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of FibroGen, Inc. (NASDAQ: FGEN). The case is currently in the lead plaintiff stage. Investors who purchased FGEN stock or other securities between November 8, 2019 and April 6, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/FibroGen to submit their information. Investors may also...
- 04/20/2021
|
FGEN LAWSUIT FILED: Jakubowitz Law Pursues Claims on Behalf of Fibrogen, Inc. Shareholders
- New York, New York--(Newsfile Corp. - April 20, 2021) - Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders FibroGen, Inc. (NASDAQ: FGEN).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/fibrogen-inc-loss-submission-form/?id=14895&from=5
- 04/20/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are advised to contact Robert S.
- 04/19/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 19, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc..Shareholders who purchased shares of FGEN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=14879&from=5CLASS PERIOD : November 8, 2019 to April 6, 2021ALLEGATIONS...
- 04/19/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - April 19, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced on behalf of investors who purchased FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=14875&wire=5Allegations against FGEN include that the Company made materially false and/or misleading statements and/or failed...
- 04/19/2021
|
Rosen, Global Investor Counsel, Encourages FibroGen, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline - FGEN
- New York, New York--(Newsfile Corp. - April 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of FibroGen, Inc. (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later...
- 04/19/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 19, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 04/19/2021
|
Kessler Topaz Meltzer & Check, LLP: Important Deadline Reminder for FibroGen, Inc. Investors in Securities Fraud Class Action Lawsuit
- RADNOR, Pa., April 19, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021 , inclusive (the "Class Period").
- 04/19/2021
|
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired FibroGen securities between November 8, 2019 and April 6, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bg
- 04/19/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 19, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 04/19/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 16, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more...
- 04/16/2021
|
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of FibroGen, Inc.Shareholders who purchased shares of FGEN during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/fibrogen-inc-loss-submission-form/?id=14802&from=5CLASS PERIOD: November 8, 2019 to April 6, 2021ALLEGAT
- 04/16/2021
|
INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the...
- 04/16/2021
|
Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc. - FGEN
- Radnor, Pennsylvania--(Newsfile Corp. - April 16, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021, inclusive (the "Class Period").Investor Deadline...
- 04/16/2021
|
FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.
- New York, New York--(Newsfile Corp. - April 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") between November 8, 2019 and April 6, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=14778&wire=5
- 04/16/2021
|
FIBROGEN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN
- New Orleans, Louisiana--(Newsfile Corp. - April 15, 2021) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11, 2021 to file lead plaintiff applications in a securities class action lawsuit against FibroGen, Inc. (NasdaqGS: FGEN), if they purchased the Company's securities and/or sold put options between November 8, 2019 and April 6, 2021, inclusive (the "Class Period"). ...
- 04/15/2021
|
FGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against FibroGen Inc.
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Gutman v. FibroGen, Inc., et al., (Case No. 3:21-cv-02725) on behalf of persons and entities that purchased or otherwise acquired FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) securities between November 8, 2019 and April 6, 2021, inclusive (the “Class Period”). Plaintiff pursu
- 04/15/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 04/15/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 04/15/2021
|
SHAREHOLDER ALERT: Robbins LLP Announces That FibroGen, Inc. (FGEN) is Being Sued for Misleading Shareholders
- SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $FGEN #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of FibroGen, Inc. (NASDAQ: FGEN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between November 8, 2019 and April 6, 2021. FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease and cancer. Its most advanced product is roxadustat. If y
- 04/15/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, April 15, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 8, 2019 and April 6, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 11, 2021.
- 04/15/2021
|
Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
- RADNOR, Pa.--(BUSINESS WIRE)---- $FGEN #classaction--Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
- 04/15/2021
|
FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
- NEW YORK, April 15, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Fibrogen, Inc., ("Fibrogen" or the "Company") (NASDAQ: FGEN) from November 8, 2019, through April 6, 2021 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.
- 04/15/2021
|
FibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
- SAN FRANCISCO, April 15, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company's anti-CTGF antibody, pamrevlumab, for the treatment of patients with Duchenne muscular dystrophy (DMD). Pamrevlumab has also received Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in two Phase 3 trials for the treatment of DMD.
- 04/15/2021
|
FibroGen Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 14, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN).If you suffered losses exceeding $50,000 investing in FibroGen stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/FGEN.
- 04/14/2021
|
FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders
- New York, New York--(Newsfile Corp. - April 14, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) alleging that the Company violated federal securities laws.Class Period: November 8, 2019 and April 6, 2021Lead Plaintiff Deadline: June 11, 2021Learn more about your recoverable losses in FGEN:
- 04/14/2021
|
FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
- RADNOR, Pa., April 14, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021 , inclusive (the "Class Period").
- 04/14/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts FibroGen (FGEN) Investors to Filing of Securities Fraud Class Action and Encourages Investors with Losses to Contact Its Attorneys Now
- San Francisco, California--(Newsfile Corp. - April 14, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now.Class Period: Nov. 8, 2019 - Apr. 6, 2021Lead Plaintiff Deadline: June 11, 2021Visit: www.hbsslaw.com/cases/FGENContact An Attorney Now: FGEN@hbsslaw.com844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Securities Fraud Action: The complaint centers on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.Throughout the Cla
- 04/14/2021
|
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of FibroGen, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 11, 2021 - FGEN
- New York, New York--(Newsfile Corp. - April 14, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of FibroGen, Inc. ("FibroGen") (NASDAQ: FGEN) between November 8, 2019 and April 6, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina. To get more information...
- 04/14/2021
|
LAWSUIT FILED: FibroGen, Inc. Sued for Violations of the Federal Securities Laws; Investors Should Contact Block & Leviton
- Boston, Massachusetts--(Newsfile Corp. - April 14, 2021) - Block & Leviton LLP (www.blockleviton.com), a national securities litigation firm, announces that a lawsuit for violations of the federal securities laws has been filed against FibroGen, Inc. (NASDAQ: FGEN) and certain of its executives. Investors should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600. The deadline to move for appointment as lead plaintiff is...
- 04/14/2021
|
SHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading
- SAN FRANCISCO, April 14, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of FibroGen, Inc. (NASDAQ: FGEN) relating to possible false statements to investors and insider trading by officers and directors. On April 6, 2021, FibroGen announced a clarification of certain prior disclosures related to roxadustat, a new drug for the treatment of anemia of chronic kidney disease.
- 04/14/2021
|
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against FibroGen, Inc. and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #ClassAction--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors that purchased FibroGen, Inc. (NASDAQ: FGEN) securities and/or sold put options from November 8, 2019 and April 6, 2021, inclusive (the “Class Period”). Investors have until June 11, 2021 to apply to the Court to be appointed as lead
- 04/13/2021
|
FIBROGEN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN
- NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 11, 2021 to file lead plaintiff applications in a securities class action lawsuit against FibroGen, Inc. (NasdaqGS: FGEN), if they purchased the Company's securities and/or sold put options between November 8, 2019 and April 6, 2021, inclusive (the “Class Period”). This action is pending in the United States Dist
- 04/13/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #investors--The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
- 04/13/2021
|
Berman Tabacco's California Office Files Securities Class Action Lawsuit Against FibroGen, Inc. (FGEN) And Announces June 11, 2021 Lead Plaintiff Deadline
- San Francisco, California--(Newsfile Corp. - April 13, 2021) - On April 12, 2021, Berman Tabacco filed a class action lawsuit for violations of the federal securities laws against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN), and certain of its current and former officers and directors, on behalf of all other persons and entities who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April 6, 2021...
- 04/13/2021
|
FGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
- NEW YORK, April 13, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired FibroGen securities between November 8, 2019 and April 6, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/fgen.
- 04/13/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc.
- 04/13/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of FibroGen Inc. (FGEN) Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) securities and/or sold put options between November 8, 2019 and April 6, 2021 inclusive (the “Class Period”). FibroGen investors have until June 11, 2021 file a lead plaintiff motion. Investors suffering losses on their FibroGen investments are encouraged to contac
- 04/13/2021
|
Berman Tabacco Files Securities Class Action Lawsuit Against FibroGen, Inc. (FGEN)
- San Francisco, California--(Newsfile Corp. - April 12, 2021) - On April 12, 2021, Berman Tabacco's California office filed a class action lawsuit for violations of the federal securities laws against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN), and certain of its current and former officers and directors, on behalf of all other persons and entities who purchased or otherwise acquired FibroGen securities and/or sold put options from November 8, 2019, through and including April...
- 04/12/2021
|
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES, April 9, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or "the Company") (NASDAQ: FGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
- 04/09/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug
- San Francisco, California--(Newsfile Corp. - April 9, 2021) - Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims.Visit: www.hbsslaw.com/investor-fraud/FGENContact An Attorney Now: FGEN@hbsslaw.com844-916-0895FibroGen, Inc. (NASDAQ: FGEN) Investigation: The investigation is focused on FibroGen's presentation of false data of roxadustat to make the anemia drug look safer than it is.In past quarters,
- 04/09/2021
|
FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of FibroGen Stockholders and Encourages Investors to Contact the Firm
- NEW YORK--(BUSINESS WIRE)-- #FederalSecuritiesLaws--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against FibroGen, Inc. (NASDAQ: FGEN) on behalf of FibroGen stockholders. Our investigation concerns whether FibroGen has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On April 6, 2021, FibroGen issued a statement “provid[ing] clarification of certain prior disclosur
- 04/08/2021
|
Berman Tabacco Investigates Potential Securities Law Violations By California-Based FibroGen Inc. (FGEN) In Connection with Roxadustat "Clarification"
- San Francisco, California--(Newsfile Corp. - April 8, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. (NASDAQ: FGEN) ("FibroGen" or the "Company"). FibroGen is a biopharmaceutical company developing roxadustat, a treatment of anemia in chronic kidney disease ("CKD").On November 8, 2019, the Company issued a press release announcing, "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic...
- 04/08/2021
|
FGEN Stock: Berger Montague Investigates Potential Securities Fraud Claims Against FibroGen, Inc. (FGEN) For Manipulating Drug Data
- Philadelphia, Pennsylvania--(Newsfile Corp. - April 8, 2021) - Berger Montague is investigating potential securities fraud claims against FibroGen, Inc. ("FibroGen" or the "Company") on behalf of investors who purchased FibroGen securities (NASDAQ: FGEN). If you purchased FibroGen securities, have questions concerning your rights or interests, or would like to discuss Berger Montague's investigation, please contact attorneys Andrew Abramowitz at aabramowitz@bm.net or (215) 875-3015, or Donnell Much at dmuch@bm.net or (215) 875-4667, or contact us at...
- 04/08/2021
|
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug
- SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Hagens Berman urges FibroGen, Inc. (NASDAQ: FGEN) investors with significant losses to submit your losses now. The firm is investigating possible securities fraud and certain investors may have valuable claims.
- 04/08/2021
|
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc.
- 04/08/2021
|
Ademi LLP Investigates Claims of Securities Fraud against FibroGen Inc.
- MILWAUKEE, April 8, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against FibroGen (NASDAQ: FGEN). The investigation results from inaccurate statements Fibrogen may have made regarding its business operations and prospects.
- 04/08/2021
|
FibroGen Investor Alert
- Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In FibroGen To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - April 7, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN).If you suffered losses exceeding $50,000 investing in FibroGen stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: http://www.faruqilaw.com/FGEN.
- 04/07/2021
|
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against FibroGen Inc.
- NEW YORK--(BUSINESS WIRE)---- $FGEN--The law firm of Kirby McInerney LLP is investigating potential claims against FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN). The investigation focuses on the Company and its officers' possible violations of federal securities laws. On April 6, 2021, after the market closed, FibroGen issued a statement “provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment
- 04/07/2021
|
The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #investors--The Law Offices of Frank R. Cruz Continues Its Investigation of FibroGen Inc. (FGEN) on Behalf of Investors
- 04/07/2021
|
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #FGEN--INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against FibroGen, Inc.
- 04/07/2021
|
Glancy Prongay & Murray LLP, a National Class Action Law Firm, Continues Investigation of FibroGen Inc. (FGEN) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a national investor rights law firm, continues its investigation on behalf of FibroGen Inc. (“Fibrogen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of the federal securities laws. If you suffered a loss on your FibroGen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your c
- 04/07/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of FibroGen Inc. (FGEN) on Behalf of Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Law Offices of Howard G. Smith continues its investigation on behalf of FibroGen Inc. (“Fibrogen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company and its officers' possible violations of federal securities laws. On April 6, 2021, after the market closed, FibroGen issued a statement “provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia
- 04/07/2021
|
Wolf Popper LLP Announces Investigation on Behalf of Purchasers of FibroGen, Inc. (FGEN) Common Stock
- NEW YORK, April 7, 2021 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of FibroGen, Inc. (NASDAQ: FGEN) common stock. FibroGen is a biopharmaceutical company.
- 04/07/2021
|
California Office of Berman Tabacco Launches Investigation into Potential Securities Claims Against FibroGen Inc. (FGEN) In Connection with Roxadustat "Clarification"
- San Francisco, California--(Newsfile Corp. - April 7, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law claims against FibroGen Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). FibroGen is a San Francisco-based biopharmaceutical company developing Roxadustat, a treatment of anemia in chronic kidney disease ("CKD").On November 8, 2019, the Company issued a press release announcing, "Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in...
- 04/07/2021
|
SHAREHOLDER ALERT: Investigation of FibroGen, Inc. Announced by Holzer & Holzer, LLC
- Atlanta, Georgia--(Newsfile Corp. - April 7, 2021) - Holzer & Holzer, LLC is investigating whether FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) complied with federal securities laws. On April 6, 2021, FibroGen made an announcement to provide "clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease." The price of FibroGen shares fell following the...
- 04/07/2021
|
Why FibroGen Stock Is Crashing Today
- The company disclosed a bombshell related to its safety results for lead candidate roxadustat.
- 04/07/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of FibroGen Inc. (“FibroGen” or the “Company”) (NASDAQ: FGEN) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your FibroGen investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws,
- 04/07/2021
|
(FGEN) Alert: Did You Lose Money on Your FibroGen Investment? Contact Johnson Fistel Regarding Investigation
- SAN DIEGO, April 7, 2021 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations of the federal securities laws by FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). On April 6, 2021, FibroGen issued a statement that reversed on some of the key safety data used to progress hope for their anemia drug roxadustat.
- 04/07/2021
|
Why FibroGen's Stock is Down During Today's Session
- FibroGen's (NASDAQ:FGEN) stock has been falling Wednesday, down 35.34% to a price of $22.25. The stock's volume is currently 2.35 million, which is roughly 176.48% of its recent 30-day volume average of 1.33 million.
- 04/07/2021
|
FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat
- FibroGen Inc (NASDAQ: FGEN) stock plummeted after hours on Tuesday after a murky disclosure for roxadustat, the company's anemia treatment in chronic kidney disease patients. While preparing for an advisory committee meeting ahead of potential approval of roxadustat, FibroGen said it realized it submitted altered information to the FDA about the drug's cardiovascular safety.
- 04/07/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $FGEN #investors--The Law Offices of Frank R. Cruz Announces Investigation of FibroGen Inc. (FGEN) on Behalf of Investors
- 04/06/2021
|
FibroGen Announces FDA Advisory Committee to Review Roxadustat New Drug Application Tentatively Scheduled for July 15, 2021
- SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced that the U.S. Food and Drug Administration (FDA) has informed the Company late today it has tentatively scheduled a Cardiovascular and Renal Drug Advisory Committee (CRDAC) on July 15, 2021 to review the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis-dependent patients.
- 04/06/2021
|
Investors Who Have Lost Money in Their FibroGen Investment Should Contact Block & Leviton, Who Is Investigating Securities Fraud Claims Against FibroGen
- Boston, Massachusetts--(Newsfile Corp. - April 6, 2021) - Block & Leviton is investigating whether FibroGen, Inc. (NASDAQ: FGEN) committed violations of securities fraud, and investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/fgen.What is this all about?After the markets closed, FibroGen admitted that prior disclosures regarding its safety analyses from the roxadustat Phase 3 program included post-hoc changes to...
- 04/06/2021
|
FibroGen stock drops as biotech clarifies data classification in study data
- FibroGen Inc. FGEN shares fell in the extended session Tuesday after the biotech drug maker said an analysis of data for its anemia drug revealed inconsistencies in how some safety data was classified. FibroGen shares dropped 22% after hours, following a 2.8% decline to close at $34.62 in the regular session.
- 04/06/2021
|
FibroGen Provides Additional Information on Roxadustat
- Company Continues to be Confident in the Benefit / Risk Profile of Roxadustat
- 04/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGE
- NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S.
- 03/24/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether FibroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...
- 03/21/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are advised to contact Robert S.
- 03/18/2021
|
FibroGen Initiates LELANTOS-2 – Second Phase 3 Clinical Study of Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
- SAN FRANCISCO, March 16, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS-2, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with ambulatory Duchenne muscular dystrophy (DMD).
- 03/16/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether FibroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...
- 03/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN). Such investors are advised to contact Robert S.
- 03/12/2021
|
The Selling In FibroGen Stock Appears Overdone After Roxadustat Delay
- The stock price of FibroGen, a biopharmaceutical company focused on therapeutics in immunology and oncology, has seen a large 36% drop over the last ten trading days, while it's down 32% over the last five trading days, but we believe the stock, after the recent drop, may trend higher in the near.
- 03/08/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN
- New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of FibroGen, Inc. ("FibroGen" or the "Company")(NASDAQ: FGEN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether FibroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class...
- 03/07/2021
|
FibroGen Stock Collapses After Its Latest-Stage Drug Faces Another Delay
- FibroGen suffered a setback after U.S. regulators requested an additional meeting before reviewing the company's anemia treatment. In response, FGEN stock crashed on Tuesday.
- 03/02/2021
|
FibroGen's (FGEN) CEO Enrique Conterno on Q4 2020 Results - Earnings Call Transcript
- FibroGen's (FGEN) CEO Enrique Conterno on Q4 2020 Results - Earnings Call Transcript
- 03/01/2021
|
FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of -120.69% and -25.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/01/2021
|
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
- • Strong Fourth Quarter China Roxadustat Net Sales of $29.2 Million and 2020 full-year Net Sales of $72.5 Million
- 03/01/2021
|
FibroGen (FGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 02/22/2021
|
FibroGen to Report Fourth Quarter and Full Year 2020 Financial Results
- SAN FRANCISCO, Feb. 18, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2020 financial results on Monday, March 1 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
- 02/18/2021
|
FibroGen to Present at Upcoming Investor Conferences
- SAN FRANCISCO, Feb. 12, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences:
- 02/12/2021
|
FibroGen: Roxadustat's U.S. Approval, 2020 China Sales, And Outsized Growth
- FibroGen, Inc. is a commercial-stage global biopharmaceutical company developing and commercializing innovative therapeutics treating anemia, fibrotic diseases, and cancer. FibroGen's pipeline consists of two late-stage/commercialized therapeutics and one medical product all with several indications each. The lead therapeutic is Roxadustat (a HIF-PHI) approved for CKD-associated anemia patients in China and Japan.
- 12/24/2020
|
FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2
- SAN FRANCISCO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced dosing of the first patient in the ZEPHYRUS-2 Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fatal lung disease.
- 12/22/2020
|
Why FibroGen Got Mashed on Monday
- The FDA delivered a discouraging update in time for the holidays.
- 12/21/2020
|
FibroGen Provides Regulatory Update on Roxadustat
- SAN FRANCISCO, Dec. 18, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period of the New Drug Application (NDA) for roxadustat for the treatment of anemia of chronic kidney disease (CKD) by three months. The updated Prescription Drug User Fee Act (PDUFA) action date is March 20, 2021.
- 12/18/2020
|
FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting
- New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndrome s (MDS) regardless of ring sideroblast (RS) or baseline e rythro poietin level
- 12/02/2020
|
FibroGen's (FGEN) Evrenzo Approved in Japan for Another Indication
- FibroGen's (FGEN) Evrenzo (roxadustat) wins second approval in Japan for treating anemia caused by chronic kidney disease in non-dialysis-dependent patients.
- 11/30/2020
|
Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
- Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis
- 11/27/2020
|
FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2020 Results - Earnings Call Transcript
- FibroGen, Inc. (FGEN) CEO Enrique Conterno on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
FibroGen to Present at Upcoming Investor Conferences
- SAN FRANCISCO, Nov. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following healthcare conferences:
- 11/06/2020
|
FibroGen (FGEN) Q3 Earnings Beat Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of 139.33% and -10.19%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
- 11/05/2020
|
FibroGen Reports Third Quarter 2020 Financial Results
- - Strong T hird Quarter China Roxadustat Net Sales of $22.7 M illion - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -
- 11/05/2020
|
FibroGen to Report Third Quarter 2020 Financial Results
- SAN FRANCISCO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2020 financial results on Thursday, November 5 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.
- 10/29/2020
|
Astellas Pharma Inc. : - New Roxadustat Data in Anemia of Chronic Kidney Disease to be released at ASN Kidney Week 2020 Reimagined | MarketScreener
|
William Blair Analysts Lift Earnings Estimates for FibroGen, Inc. (NASDAQ:FGEN)
- FibroGen, Inc. (NASDAQ:FGEN) – Equities researchers at William Blair upped their Q3 2020 earnings per share estimates for shares of FibroGen in a research report issued to clients and investors on Tuesday, October 13th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will post earnings per share of ($0.92) for the quarter, […]
- 10/17/2020
|
Europe Sickle Cell Anemia Market and Competitive Landscape 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, and Market Shares 2016-2024 - ResearchAndMarkets.com
|
Engineers Gate Manager LP Has $252,000 Holdings in FibroGen Inc (NASDAQ:FGEN)
- Engineers Gate Manager LP lessened its stake in shares of FibroGen Inc (NASDAQ:FGEN) by 7.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,212 shares of the biopharmaceutical company’s stock after selling 494 shares during the period. Engineers Gate Manager LP’s […]
- 09/28/2020
|
FibroGen Inc (NASDAQ:FGEN) Shares Bought by Vanguard Group Inc.
- Vanguard Group Inc. lifted its holdings in FibroGen Inc (NASDAQ:FGEN) by 5.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,548,004 shares of the biopharmaceutical company’s stock after acquiring an additional 419,060 shares during the period. Vanguard Group Inc. owned approximately […]
- 09/19/2020
|
Tudor Investment Corp Et Al Purchases New Stake in FibroGen Inc (NASDAQ:FGEN)
- Tudor Investment Corp Et Al bought a new stake in FibroGen Inc (NASDAQ:FGEN) during the second quarter, HoldingsChannel.com reports. The firm bought 10,710 shares of the biopharmaceutical company’s stock, valued at approximately $434,000. A number of other institutional investors have also added to or reduced their stakes in the business. Wells Fargo & Company MN […]
- 09/16/2020
|
Rafferty Asset Management LLC Purchases 18,671 Shares of FibroGen Inc (NASDAQ:FGEN)
- Rafferty Asset Management LLC boosted its position in FibroGen Inc (NASDAQ:FGEN) by 293.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,029 shares of the biopharmaceutical company’s stock after purchasing an additional 18,671 shares during the quarter. Rafferty Asset Management LLC’s holdings in […]
- 08/25/2020
|
FibroGen Announces First Patient Enrolled in Pamrevlumab Phase 3 Clinical Trial in Patients with Duchenne Muscular Dystrophy
- SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab or placebo in combination with systemic corticosteroids in patients with non-ambulatory Duchenne muscular dystrophy (DMD).The primary objective of this global study is to evaluate the effect of pamrevlumab on muscle function in patients with DMD. Approximately 90 patients will be randomized 1:1 to receive pamrevlumab plus systemic corticosteroids, or placebo plus systemic corticosteroids, for up to 52 weeks. The primary efficacy endpoint is the change in the total score of performance of upper limb (PUL) assessment, from baseline to Week 52, and additional endpoints include pulmonary and cardiac function tests. Subjects who complete the 52-week study will be eligible for rollover into an open-label extension study with pamrevlumab and systemic corticosteroids.“Duchenne muscular dystrophy is a progressive disease associated with muscle deterioration and weakness, often leading to patients becoming wheelchair-bound by the age of 12,” said Elias Kouchakji, M.D., Senior Vice President, Clinical Development, Drug Safety, and Pharmacovigilance, FibroGen. “In DMD, inhibition of connective tissue growth factor (CTGF) by pamrevlumab could result in decreased fibrosis in muscles leading to increased muscle function. We hope pamrevlumab provides a meaningful treatment for the patients with this debilitating disease.” Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of CTGF, a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Importantly, skeletal muscle from DMD patients shows elevated levels of CTGF, and a major manifestation of DMD is cardiac fibrosis.“Initiation of the LELANTOS Phase 3 clinical trial represents a key milestone for FibroGen and for our DMD clinical program, as well as an important development for the patients and families affected by Duchenne,” said Enrique Conterno, Chief Executive Officer, FibroGen. “We are grateful for the collaboration of global regulators, investigators, caregivers, and patients in enabling the conduct of this trial.”About Pamrevlumab Pamrevlumab is a first-in-class antibody developed by FibroGen that inhibits the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD); and in Phase 2 clinical development for coronavirus (COVID-19). For information about pamrevlumab studies currently recruiting patients, please visit www.clinicaltrials.gov.About Duchenne Muscular Dystrophy Duchenne muscular dystrophy is a rare and debilitating neuromuscular disease that affects approximately 1 in every 3,500 newborn boys. The fatal disease is caused by a genetic mutation leading to the absence or defect of dystrophin, a protein necessary for normal muscle function. The absence of dystrophin results in muscle weakness, muscle loss, fibrosis, and inflammation. Patients with DMD are often wheelchair-bound before the age of 12, and their progressive muscle weakness may lead to serious medical problems relating to respiratory and cardiac muscle.About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For more information, please visit www.fibrogen.com.Forward-Looking Statements This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development and commercialization of the company’s product candidates, the potential safety and efficacy profile of our product candidates, our clinical programs and regulatory events, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and our Quarterly Report on Form 10-Q for quarter ended March 31, 2020, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.Contact: FibroGen, Inc.Media Inquiries: Sara Iacovino 1.703.474.4452 sara.iacovino@gcihealth.comInvestors: Michael Tung, M.D. Corporate Strategy / Investor Relations 1.415.630.0131 mtung@fibrogen.com
- 08/11/2020
|
Zafgen (NASDAQ:ZFGN) vs. FibroGen (NASDAQ:FGEN) Head-To-Head Comparison
- Zafgen (NASDAQ:ZFGN) and FibroGen (NASDAQ:FGEN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends. Risk & Volatility Zafgen has a beta of 0.27, meaning that its share price is 73% less volatile […]
- 08/11/2020
|
FibroGen (FGEN) Gets a Buy Rating from Leerink Partners - Markets
- In a report released today, Geoff Porges from Leerink Partners maintained a Buy rating on FibroGen (FGEN – Research Report),
- 08/07/2020
|
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of -61.02% and 22.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/07/2020
|
FibroGen Reports Second Quarter 2020 Financial Results
- \- Strong Second Quarter China Roxadustat Net Sales of $15.7 million - \- Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) reported financial results for the second quarter of 2020 and provided an update on the company’s recent developments.“Despite this difficult time, we continue to be inspired by our unique opportunity to leverage world-class science to benefit patients,” said Enrique Conterno, Chief Executive Officer, FibroGen. “I am pleased with the progress we are making with roxadustat across a number of fronts; including our engagement with the FDA, the European submission, and our impressive sales in China. Additionally, we recently initiated three new trials with pamrevlumab: our Phase 3 study with DMD and two trials in patients hospitalized with COVID-19.”Key Events in Recent Months and Other Developments Roxadustat * U.S. NDA for roxadustat for the treatment of anemia of chronic kidney disease (CKD), in dialysis-dependent and non-dialysis-dependent patients, is under review with a Prescription Drug User Fee Act (PDUFA) date of December 20, 2020. * Marketing authorization application (MAA) for roxadustat for the treatment of anemia in adult patients with CKD, both on dialysis and not on dialysis, accepted by the European Medicines Agency (EMA) for regulatory review in May. * Japan sNDA for roxadustat for the treatment of anemia of CKD in non-dialysis-dependent patients is under review. * Presented results from the DOLOMITES Phase 3 study at the 57th ERA-EDTA Virtual Congress in which roxadustat demonstrated non-inferiority to darbepoetin alfa in achievement of hemoglobin correction in non-dialysis-dependent patients with CKD. * Continued enrollment of Phase 3 roxadustat clinical trial in anemia associated with myelodysplastic syndromes (MDS) and Phase 2 roxadustat clinical trial in chemotherapy-induced anemia (CIA).Pamrevlumab * Initiated a randomized, double-blind, placebo-controlled Phase 2 study investigating the efficacy and safety of pamrevlumab in approximately 130 hospitalized patients with acute COVID-19 infection in the U.S. * Initiated BOREA, a Phase 2/3 investigator-initiated clinical trial investigating the efficacy and safety of pamrevlumab in approximately 68 patients hospitalized with COVID-19 in Italy. * Reopened enrollment of the ZEPHYRUS Phase 3 clinical trial of pamrevlumab in patients with IPF after pausing for two months to minimize the risk of exposure to COVID-19. * Continued enrollment of the LAPIS Phase 3 clinical trial of pamrevlumab in patients with locally advanced unresectable pancreatic cancer (LAPC).Upcoming Events * Plan to initiate ZEPHYRUS 2, a second IPF Phase 3 clinical trial similar in size and design to ZEPHYRUS, as COVID-19 conditions improve. * Plan to initiate LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab in approximately 90 patients with non-ambulatory Duchenne muscular dystrophy (DMD).Corporate and Financial * Total revenue for the second quarter of 2020 was $42.9 million, as compared to $191.6 million for the second quarter of 2019. The current quarter revenue consisted of $15.7 million in net roxadustat sales in China, $19.0 million in development revenue, and $8.2 million in roxadustat API sales to Astellas in Japan. * Net loss for the second quarter of 2020 was $85.3 million, or $0.95 net loss per basic and diluted share, compared to a net income of $116.0 million, or $1.34 net income per basic share and $1.26 per diluted share one year ago. * At June 30, 2020, FibroGen had $716.0 million in cash, cash equivalents, restricted time deposits, investments, and receivables. * Based on our latest forecast, we reiterate our year-end 2020 estimate to be in the range of $720 to $730 million in cash, cash equivalents, restricted time deposits, investments, and receivables. * Amended China Agreement with AstraZeneca in July 2020 such that both parties are optimally aligned to maximize the economic value of the roxadustat franchise, with more predictable economics and profitability for FibroGen. * Appointed Thane Wettig to the newly-created position of Chief Commercial Officer. * Appointed Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic, Inc. (NASDAQ:SYBX) to board of directors effective August 5, 2020. * Appointed Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute to board of directors effective August 5, 2020.Conference Call and Webcast Details FibroGen will host a conference call and webcast today, Thursday, August 6, 2020, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss financial results and provide a business update. A live audio webcast of the call may be accessed in the investor section of the company’s website, www.fibrogen.com. To participate in the conference call by telephone, please dial 1 (877) 658-9081 (U.S. and Canada) or 1 (602) 563-8732 (international), reference the FibroGen second quarter 2020 financial results conference call, and use passcode 8363719. A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international) and use passcode 8363719.About Roxadustat Roxadustat is a first-in-class, orally administered small molecule HIF-PH inhibitor that promotes erythropoiesis through increasing endogenous production of erythropoietin, and improved iron absorption, transport and mobilization. Roxadustat is approved in China for the treatment of anemia in adult patients with CKD, both on dialysis and not on dialysis. In Japan it is approved for the treatment of anemia in CKD patients on dialysis and a supplemental NDA for the treatment of anemia in CKD patients not on dialysis is under regulatory review. The roxadustat NDA for the treatment of anemia in CKD is under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act date of December 20, 2020. The Marketing Authorization Application for roxadustat for the treatment of anemia in CKD was filed by our partner Astellas and accepted by the European Medicines Agency for review on May 21, 2020. Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in territories including Japan and Europe. AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment of anemia in the U.S., China, and other markets.About Pamrevlumab Pamrevlumab is a first-in-class antibody developed by FibroGen that inhibits the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and locally advanced unresectable pancreatic cancer (LAPC), and in Phase 2 clinical development for the treatment of Duchenne muscular dystrophy (DMD) and coronavirus (COVID-19). For information about pamrevlumab studies currently recruiting patients, please visit www.clinicaltrials.gov.About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For more information, please visit www.fibrogen.com.Forward-Looking Statements This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development and commercialization of the company’s product candidates, our financial results, the potential safety and efficacy profile of our product candidates, our clinical programs and regulatory events, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and our Quarterly Report on Form 10-Q for quarter ended June 30, 2020 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein.
- 08/06/2020
|
FibroGen Announces New Appointments to its Board of Directors
- \- Appoints Aoife Brennan, M.B., B.Ch., President and CEO of Synlogic Inc. (NASDAQ:SYBX) - \- Appoints Ben Cravatt, Ph.D., Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute -SAN FRANCISCO, Aug. 06, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Dr. Aoife Brennan and Dr. Ben Cravatt to its Board of Directors effective August 5, 2020. Dr. Brennan is President and CEO of Synlogic Inc. (Nasdaq:SYBX), a clinical stage biotechnology company bringing the transformative potential of synthetic biology to medicine. She joined Synlogic as Chief Medical Officer in 2016 and was promoted to CEO in October 2018. Dr. Cravatt is a Professor and the Norton B. Gilula Chair of Chemical Biology in the Department of Chemistry at The Scripps Research Institute. His research group is interested in developing chemical proteomic technologies that enable protein and drug discovery on a global scale and applying these methods to characterize biochemical pathways that play important roles in human physiology and disease. Professor Cravatt joined the faculty at The Scripps Research Institute in 1997.“We are honored to welcome both Aoife and Ben to our Board of Directors at this exciting point in FibroGen’s history. Aoife’s deep experience in rare diseases and clinical development, and Ben’s world-class expertise in biology and chemistry will provide invaluable perspective to our Board.” said Enrique Conterno, Chief Executive Officer, FibroGen. * “I very much look forward to working with Mr. Conterno and the other Directors to deliver on the unlimited potential of FibroGen and its exciting portfolio of innovative medicines to address major unmet needs in human health and disease.” said Dr. Cravatt. * “I am excited to join FibroGen's Board as the company moves to accelerate pivotal study development of pamrevlumab in multiple orphan indications, and toward approval and launch of roxadustat for the treatment of anemia associated with CKD worldwide, as well as expanding into additional indications for the treatment of anemia,” Dr. Brennan added. “I look forward to working with Enrique and the entire Board of Directors to advance these important products.”Prior to joining Synlogic, Dr. Brennan served as Vice President and Head of the Rare Disease Innovation Unit at Biogen where her responsibilities included the global marketing approvals of ALPROLIX™, ELOCTATE™ and SPINRAZA™ as well as the advancement of several early-phase programs and external collaborations. She served as a Director of Ra Pharmaceuticals from Sept 2018 through its acquisition in April 2020. Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and completed residency and fellowship training in general internal medicine and endocrinology. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.A Professor at Scripps Research for more than twenty years, Dr. Cravatt is an Associate Editor for Journal of the American Chemical Society and is a co-founder of Activx Biosciences, Abide Therapeutics, and Vividion Therapeutics. He serves on the Board of Directors of Vividion, Boundless Bio, and Autobahn Therapeutics. Dr. Cravatt’s honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the RSC Jeremy Knowles Award, the AACR Award for Achievement in Chemistry in Cancer Research, and memberships in the American Academy of Arts and Sciences, National Academy of Inventors, National Academy of Medicine, and National Academy of Sciences. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute in 1996.“I am delighted to welcome Drs. Brennan and Cravatt to the FibroGen Board of Directors,” said Jim Schoeneck, chairman of the FibroGen’s Board. “Both will bring fresh perspectives that will help the Board and management advance our clinical development and research agendas to bring potential first-in-class medicines to patients suffering from chronic or life-threatening conditions.”About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For more information, please visit www.fibrogen.com.Forward-Looking Statements This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development and commercialization of the company’s product candidates. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and our Quarterly Report on Form 10-Q for quarter ended June 30, 2020 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.Contact: FibroGen, Inc.Media Inquiries: Sara Iacovino 1.703.474.4452 sara.iacovino@gcihealth.comInvestors: Michael Tung, M.D. Corporate Strategy / Investor Relations 1.415.978.1434 mtung@fibrogen.com
- 08/06/2020
|
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
- 08/06/2020
|
FibroGen (NASDAQ:FGEN) Stock Rating Lowered by Zacks Investment Research
- FibroGen (NASDAQ:FGEN) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Monday, Zacks.com reports. According to Zacks, “FibroGen, Inc. is a research-based biotechnology company. It is focused on the discovery, development, and commercialization of therapeutic agents for treatment of anemia, fibrosis, cancer, and other serious […]
- 08/05/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
- FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/30/2020
|
What Type Of Shareholders Make Up FibroGen, Inc.'s (NASDAQ:FGEN) Share Registry?
- If you want to know who really controls FibroGen, Inc. (NASDAQ:FGEN), then you'll have to look at the makeup of its...
- 07/24/2020
|
FibroGen to Report Second Quarter 2020 Financial Results
- SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events. It is recommended that listeners access the website 15 minutes prior to the start of the call to download and install any necessary audio software.Dial-In Information Live (U.S./Canada): (877) 658-9081 Live (International): (602) 563-8732 Confirmation number: 8363719A replay of the webcast will be available shortly after the call for a period of two weeks. To access the replay, please dial (855) 859-2056 (domestic) or (404) 537-3406 (international), and use passcode 8363719.About FibroGen FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics. The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs. The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD). Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, Duchenne muscular dystrophy (DMD), and coronavirus (COVID-19). For more information, please visit www.fibrogen.com.Contact: FibroGen, Inc.Media Inquiries: Sara Iacovino 1.703.474.4452 sara.iacovino@gcihealth.comInvestors: Michael Tung, M.D. Corporate Strategy / Investor Relations 1.415.978.1434 mtung@fibrogen.com
- 07/23/2020
|
Did Hedge Funds Make The Right Call On FibroGen Inc (FGEN) ?
- The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]
- 07/17/2020
|
Engineers Gate Manager LP Takes $233,000 Position in FibroGen Inc (NASDAQ:FGEN)
- Engineers Gate Manager LP purchased a new stake in FibroGen Inc (NASDAQ:FGEN) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,706 shares of the biopharmaceutical company’s stock, valued at approximately $233,000. Several other hedge funds have also recently made […]
- 07/04/2020
|
Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors
- Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors
- 07/01/2020
|
GSK's kidney disease anaemia drug approved in Japan, taking on Astellas' rival -
- GlaxoSmithKline’s drug for anaemia caused by chronic kidney disease daprodustat has been approved in Japan, taking on a recently approved rival from Astellas.
- 06/29/2020
|
Xconomy: Bio Roundup: Gilead's Pionyr Grab, Relay to IPO, Unicorn Sana & More
- Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside
- 06/26/2020
|
FibroGen Begins Phase II Study for Acute Coronavirus in US
- FibroGen (FGEN) enrolls the first patient in a placebo-controlled phase II study on pamrevlumab in hospitalized patients with acute COVID-19 infection in the United States.
- 06/24/2020
|
FIBROGEN INC : Change in Directors or Principal Officers (form 8-K) | MarketScreener
|
Sarepta Addressing Gene Therapy Issue With Two Acquisitions
- Biotech’s shares trading near all-time high of $172. It is also working on Covid-19 treatment Continue reading...
- 06/23/2020
|
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19 | MarketScreener
|
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
- FibroGen, Inc. (FGEN) today announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 Study investigating the efficacy and safety of pamrevlumab in hospitalized patients with acute coronavirus 2019 (COVID-19) infection. This multicenter trial is being conducted in the U.S. and will enroll approximately 130 patients with COVID-19. The primary objective of this study is to assess the effect of pamrevlumab on blood oxygenation in patients with COVID-19 infection, and patients will be randomized to treatment with pamrevlumab or standard of care in a 1:1 ratio.
- 06/23/2020
|
FibroGen Appoints Thane Wettig as Chief Commercial Officer | MarketScreener
|
FibroGen Appoints Thane Wettig as Chief Commercial Officer
- FibroGen, Inc. (FGEN) announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more than 30 years of global biopharmaceutical leadership and experience. “I am excited to welcome Thane to FibroGen as our new Chief Commercial Officer,” said Enrique Conterno, Chief Executive Officer, FibroGen.
- 06/22/2020
|
Two Sigma Investments LP Lowers Stock Holdings in FibroGen Inc (NASDAQ:FGEN)
- Two Sigma Investments LP lowered its stake in shares of FibroGen Inc (NASDAQ:FGEN) by 63.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 42,335 shares of the biopharmaceutical company’s stock after selling 74,610 shares during the quarter. Two Sigma Investments LP’s […]
- 06/22/2020
|
Mackenzie Financial Corp Buys Shares of 6,900 FibroGen Inc (NASDAQ:FGEN)
- Mackenzie Financial Corp bought a new stake in shares of FibroGen Inc (NASDAQ:FGEN) in the first quarter, according to its most recent Form 13F filing with the SEC. The fund bought 6,900 shares of the biopharmaceutical company’s stock, valued at approximately $240,000. A number of other institutional investors have also recently bought and sold shares […]
- 06/22/2020
|
Geode Capital Management LLC Grows Stake in FibroGen Inc (NASDAQ:FGEN)
- Geode Capital Management LLC raised its holdings in FibroGen Inc (NASDAQ:FGEN) by 7.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,197,118 shares of the biopharmaceutical company’s stock after buying an additional 80,593 shares during the quarter. Geode Capital Management LLC owned about […]
- 06/22/2020
|
Why Novartis Stock Is Trading Higher Today
- Novartis (NYSE: NVS) shares are trading higher on Wednesday after the company announced it received FDA approval for its Cosentyx for a new indication to treat active non-...
- 06/17/2020
|
Hedge Funds Are Nibbling On FibroGen Inc (FGEN)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 06/16/2020
|
Weekly CEO Buys Highlight: Camping World, FibroGen
- Details the CEO buys this past week for the following companies: FibroGen, Quidel, Camping World Holdings, B. Riley Financial and Ranpak Holdings Continue reading...
- 06/15/2020
|
FibroGen (NASDAQ:FGEN) Rating Increased to Sell at BidaskClub
- FibroGen (NASDAQ:FGEN) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday, BidAskClub reports. A number of other brokerages have also commented on FGEN. TheStreet lowered shares of FibroGen from a “c-” rating to a “d” rating in […]
- 06/15/2020
|
Xconomy: Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More
- At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the
- 06/12/2020
|
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher
- FibroGen (FGEN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
- 06/11/2020
|
Kiniksa Positive COVID-19 Data And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:KNSA)
- Kiniksa announces positive COVID-19 trial. Astellas Phase 3 anemia study reports positive data. Enochian BioSciences progresses with HIV drug.
- 06/10/2020
|
-$0.59 Earnings Per Share Expected for FibroGen Inc (NASDAQ:FGEN) This Quarter
- Equities research analysts expect FibroGen Inc (NASDAQ:FGEN) to announce earnings per share (EPS) of ($0.59) for the current quarter, Zacks reports. Four analysts have provided estimates for FibroGen’s earnings, with estimates ranging from ($1.07) to $0.57. FibroGen reported earnings of $1.26 per share during the same quarter last year, which suggests a negative year-over-year growth […]
- 06/10/2020
|
FIBROGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K) | MarketScreener
|
Astellas Pharma : Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia | MarketScreener
|
FibroGen Initiates Phase II/III Study in Severe Coronavirus
- FibroGen (FGEN) starts a phase II/III study in Italy on pamrevlumab versus standard of care in patients with severe COVID-19 infection.
- 06/09/2020
|
FibroGen Announces New Roxadustat Data Presented At 2020 ERA-EDTA Virtual Congress
|
FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress | MarketScreener
|
FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress
- Roxadustat demonstrates non-inferiority to darbepoetin alfa in achievement of Hb correction in DOLOMITES Phase 3 study of anemia in non-dialysis dependent patients with chronic.
- 06/08/2020
|
FibroGen : AstraZeneca presents new data across continuum of care from its broad renal portfolio at ERA-EDTA 2020 Virtual Congress | MarketScreener
|
FibroGen Announces First Patient Enrolled In Pamrevlumab Clinical Trial In Patients Hospitalized In Italy With Severe COVID-19
|
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19 | MarketScreener
|
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
- FibroGen, Inc. (FGEN) today announced the initiation of an open-label, randomized, parallel-arm study investigating the efficacy and safety of pamrevlumab versus standard of care in patients with severe coronavirus 2019 (COVID-19) infection. The trial is being conducted by Professor Luca Richeldi, M.D., Ph.D., Head of the Division of Pulmonary Medicine at Fondazione Policlinico Universitario A. Gemelli IRCCS, and Professor of Respiratory Medicine at Catholic University of the Sacred Heart in Rome, Italy. BOREA is a Phase 2/3 investigator-initiated clinical trial investigating the efficacy and safety of pamrevlumab in approximately 68 patients hospitalized with COVID-19.
- 06/08/2020
|
FibroGen Inc (NASDAQ: FGEN) Q1 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of FibroGen Inc. - FGEN stock
- 06/02/2020
|
Akebia Therapeutics: A Clear Path To A Blockbuster CKD-Anemia Treatment (NASDAQ:AKBA)
- Akebia has taken a significant step towards securing approval for Vadadustat, its potential blockbuster treatment for anemia in CKD sufferers. Data from the pha
- 06/01/2020
|
FibroGen to Present at Upcoming Investor Conferences | MarketScreener
|
FibroGen to Present at Upcoming Investor Conferences
- SAN FRANCISCO, May 27, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following.
- 05/27/2020
|
Astellas Pharma And FibroGen Announce European Medicines Agency Accepts Astellas' Marketing Authorization Application For Roxadustat
|
European Medicines Agency Accepts Astellas’ Marketing Authorization Application for Roxadustat
- TOKYO and SAN FRANCISCO, May 21, 2020 -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique.
- 05/21/2020
|
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat
- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the marketing authorization application (MAA) for roxadustat for the treatment of anemia in adult patients with chronic kidney disease (CKD) has been accepted by the European Medicines Agency (EMA) for regulatory review.
- 05/21/2020
|
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
- 05/21/2020
|
Sarah O’Dowd Joins Ichor Board of Directors
- Ichor Holdings, Ltd. (NASDAQ: ICHR), a leader in the design, engineering, and manufacturing of critical fluid delivery subsystems for semiconductor ca
- 05/14/2020
|
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and aut
- 05/13/2020
|
FibroGen, Inc. (NASDAQ:FGEN) Analysts Are Cutting Their Estimates: Here's What You Need To Know
- FibroGen, Inc. (NASDAQ:FGEN) just released its latest first-quarter report and things are not looking great. Statutory...
- 05/11/2020
|
FibroGen Inc (FGEN) Q1 2020 Earnings Call Transcript
- Ladies and gentlemen, thank you for standing by, and welcome to the FibroGen First Quarter 2020 Financial Results. Thank you for joining us on today's call to discuss FibroGen's results for the first quarter of 2020. Today's call will be led by Enrique Conterno, our Chief Executive Officer.
- 05/09/2020
|
Edited Transcript of FGEN earnings conference call or presentation 7-May-20 9:00pm GMT
- Q1 2020 FibroGen Inc Earnings Call
- 05/09/2020
|
Edited Transcript of FGEN earnings conference call or presentation 7-May-20 9:00pm GMT
- Q1 2020 FibroGen Inc Earnings Call
- 05/08/2020
|
SVB Leerink Maintains Outperform on FibroGen, Lowers Price Target to $80
|
U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
- Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Computer Programs and Systems Inc : Cantor Fitzgerald raises to overweight from neutral
* Epam Systems Inc : Citigroup raises price target to $265 from $245
* PayPal Holdings Inc : Citigroup raises price target to $145 from $131
Following is a summary of research actions on U.S. companies reported by Reuters on Friday. Stock entries are in alphabetical
order.
* Aaron's Inc : Keybanc cuts target price to $55 from $66
* Aaron's Inc : Raymond James cuts target price to $50 from $60
* Aaron's Inc : Stephens raises target price to $45 from $26
* Abeona Therapeutics Inc : RBC cuts target price to $7 from $11
* Acceleron pharma Inc : Credit Suisse raises target price to $123 from $99
* ACI Worldwide Inc : Canaccord Genuity cuts target price to $35 from $44
* Acushnet Holdings Corp : Jefferies raises target price to $25 from $24
* Acushnet Holdings Corp : JP Morgan raises target price to $30 from $27
* Adtran Inc : Cowen and Company raises price target to $13 from $9
* Aeglea Bio Therapeutics Inc : Needham cuts price target to $11 from $14
* Aerie Pharmaceuticals Inc : Citigroup cuts price target to $38 from $39
* Agco Corp : Citigroup cuts price target to $55 from $57
* AIG : KBW raises target price to $36 from $35
* Alaska Air Group Inc : Credit Suisse cuts target price to $51 from $82
* Allison Transmission Holdings Inc : Citigroup raises price target to $39 from $38
* Allscripts Healthcare Solutions : Cantor Fitzgerald cuts PT to $6 from $8
* Alteryx Inc : Guggenheim cuts target price to $130 from $160
* American Airlines : Credit Suisse cuts target price to $4 from $26
* Ameriprise Financial Inc : Credit Suisse raises target price to $165 from $153
* Ameriprise Financial Inc : Piper Sandler raises target price to $150 from $130
* Amerisourcebergen Corp : Baird raises target price to $115 from $109
* Amerisourcebergen Corp : Mizuho raises target price to $90 from $85
* Amtech Systems Inc : Cowen and Company raises target price to $7.50 from $7
* Angi Homeservices Inc : Needham raises target price to $11 from $8
* Ani Pharmaceuticals Inc : Guggenheim cuts target price to $48 from $58
* Ansys Inc : RBC raises target price to $260 from $230
* Anthem Inc : Bernstein raises target price to $357 from $342
* Appian Corp : Cowen and Company raises price target to $44 from $39
* Applied Optoelectronics Inc : D.A. Davidson raises target price to $12 from $10
* Applied Optoelectronics Inc : Piper Sandler raises target price to $10 from $7.50
* Aptiv Plc : Citigroup raises price target to $84 from $67
* ArcelorMittal SA : Keybanc raises target price to $15 from $13
* Arcturus Therapeutics Holdings Inc : Baird raises target price to $44 from $26
* Arcturus Therapeutics Holdings Inc : Guggenheim raises target price to $51 from $41
* Ares Capital Corp : Citigroup raises price target to $15 from $13
* Athersys Inc : Needham cuts price target to $5 from $6
* Atlas Air Worldwide Holdings Inc : Cowen and Company raises PT to $44 from $40
* Avalara Inc : Canaccord Genuity raises target price to $115 from $105
* Avalara Inc : JP Morgan raises target price to $120 from $104
* Avalara Inc : Mizuho raises price target to $120 from $85
* Avalara Inc : Piper Sandler raises target price to $113 from $90
* Avalonbay Communities Inc : Stifel raises target price to $176 from $171
* Avrobio Inc : Guggenheim raises target price to $50 from $49
* Axalta Coating Systems Ltd : RBC raises target price to $21 from $20
* Bausch Health Companies Inc : Piper Sandler cuts target price to $32 from $34
* Beacon Roofing Supply Inc : SunTrust Robinson raises target price to $26 from $24
* Beacon Roofing Supply Inc : Wedbush raises target price to $23 from $16
* Becton Dickinson and Co : Citigroup raises price target to $260 from $234
* Becton Dickinson and Co : Evercore ISI raises target price to $270 from $255
* Beyond Meat Inc : Berenberg raises price target to $125 from $115
* Bill.Com Holdings Inc : Canaccord Genuity raises target price to $65 from $50
* Bill.Com Holdings Inc : Jefferies raises target price to $70 from $45
* Bill.Com Holdings Inc : Keybanc raises target price to $76 from $60
* Bill.Com Holdings Inc : Needham raises target price to $90 from $55
* Biomarin Pharmaceutical Inc : Canaccord Genuity raises PT to $119 from $108
* BJ's Restaurants Inc : Wedbush cuts target price to $32 from $39
* Booking Holdings Inc : Credit Suisse raises target price to $1,810 from $1,790
* Booking Holdings Inc : Jefferies cuts target price to $1300 from $1350
* Booking Holdings Inc : Mizuho cuts price target to $1700 from $1720
* Booking Holdings Inc : RBC raises target price to $1,550 from $1,535
* Booking Holdings Inc : RBC raises target price to $1550 from $1535
* BorgWarner Inc : Citigroup raises price target to $30 from $23
* BorgWarner Inc : Credit Suisse raises target price to $33 from $31
* Bottomline Technologies (De) Inc : Citigroup raises price target to $46 from $43
* Bright Horizons Family Solutions Inc : Citigroup raises PT to $122 from $80
* Brightsphere Investment Group Inc : Evercore ISI raises target to $9 from $6
* Brightsphere Investment Group Inc : KBW raises target price to $9.50 from $7.25
* Brightview Holdings Inc : Credit Suisse cuts target price to $14 from $18
* Brightview Holdings Inc : Jefferies raises target price to $14 from $12
* Cabot Microelectronics Corp : Citigroup cuts price target to $140 from $175
* Cactus Inc : zephirin Group raises price objective to $12 from $8
* Calithera Biosciences Inc : Jefferies raises target price to $9 from $6
* Calyxt Inc : BMO cuts price target to $7 from $13
* Calyxt Inc : BMO cuts to market perform from outperform
* Camping World Holdings Inc : Credit Suisse raises target price to $12 from $11
* Camping World Holdings Inc : JP Morgan raises price target to $11 from $10
* Capstar Financial Holdings Inc : KBW raises target price to $11 from $10.50
* Cargurus Inc : BTIG raises target price to $26 from $23
* Carrols Restaurant Group Inc : Craig-Hallum raises to buy from hold; raises target price to $5 from $3.75
* Castlight Health Inc : Cantor Fitzgerald cuts target price to $1 from $2
* Catasys Inc : Canaccord Genuity raises target price to $36 from $35
* CBRE Group Inc : Evercore ISI cuts target price to $48 from $50
* CBRE Group Inc : KBW cuts target price to $51 from $52
* Centerpoint Energy Inc : Guggenheim raises target price to $26 from $25
* Centerpoint Energy Inc : Keybanc raises target price to $16 from $12
* Centurylink Inc : RBC cuts target price to $10 from $14
* CF Industries Holdings Inc : Citigroup cuts price target to $29 from $31
* CF Industries Holdings Inc : Scotiabank raises target price to $32 from $31
* ChannelAdvisor Corp : Needham raises price target to $14 from $11
* Charles River Laboratories International : Credit Suisse cuts PT to $159 from $162
* Charles River Laboratories International : Evercore ISI ups PT to $176 from $154
* Charles River Laboratories International : Jefferies raises PT to $161 from $139
* Charles River Laboratories International Inc : Citigroup raises price target to $190 from $165
* Chart Industries Inc : zephirin Group raises price objective to $25 from $17
* Charter Communications Inc : Benchmark raises price target to $600 from $523
* Chemours Co : Citigroup raises price target to $13 from $8
* Cimarex Energy Co : MKM Partners raises target price to $34 from $31
* City Holding Co : Stephens cuts target price to $63 from $64.
- 05/08/2020
|
FibroGen to Present at Bank of America Securities 2020 Health Care Conference
- SAN FRANCISCO, May 08, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) will participate in the Bank of America Securities 2020 Health Care Conference that is being held virtually on May.
- 05/08/2020
|
FibroGen (FGEN) Reports Q1 Loss, Lags Revenue Estimates
- FibroGen (FGEN) delivered earnings and revenue surprises of -196.67% and -64.10%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
- 05/08/2020
|
FibroGen to Present at Bank of America Securities —…—… Health Care Conference
|
FibroGen Q1 EPS $(0.890) Down From $(0.530) YoY, Sales $24.401M Up From $23.863M YoY
|
FibroGen Reports First Quarter 2020 Financial Results
- - Roxadustat U.S. NDA review and E.U. MAA filing on track - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, May 07, 2020 -- FibroGen,.
- 05/07/2020
|
Akebia Shares Climb on Positive Anemia Drug Study Results
- Company hits 52-week high of $12.25 Continue reading...
- 05/07/2020
|
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
- 05/07/2020
|
Why FibroGen (FGEN) Might Surprise This Earnings Season
- FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 05/06/2020
|
Why FibroGen (FGEN) Might Surprise This Earnings Season
|
How Does Investing In FibroGen, Inc. (NASDAQ:FGEN) Impact The Volatility Of Your Portfolio?
- Anyone researching FibroGen, Inc. (NASDAQ:FGEN) might want to consider the historical volatility of the share price...
- 05/03/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?
- The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- 05/01/2020
|
FibroGen initiated with a Market Perform at Cowen FGEN
- FibroGen initiated with a Market Perform at Cowen Cowen FGEN
- 05/01/2020
|
Cowen & Co. Initiates Coverage On FibroGen with Market Perform Rating, Announces Price Target to $40
|
Benzinga's Top Upgrades, Downgrades For May 1, 2020
|
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
- FibroGen (FGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2020
|
FibroGen (FGEN) Set to Announce Quarterly Earnings on Thursday
- FibroGen (NASDAQ:FGEN) is set to issue its quarterly earnings data after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.40) per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link. FibroGen (NASDAQ:FGEN) last posted its quarterly […]
- 04/30/2020
|
FibroGen (NASDAQ:FGEN) Research Coverage Started at Bank of America
- Bank of America assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a report published on Monday, Benzinga reports. The brokerage issued a neutral rating and a $45.00 price objective on the biopharmaceutical company’s stock. Several other equities analysts also recently issued reports on the company. Mizuho reiterated a buy rating and issued a $72.00 price […]
- 04/30/2020
|
BHK Investment Advisors, LLC Buys PIMCO …-5 Year High Yield Corporat Bond Index Exch, ...
|
Fly Intel: Top five analyst initiations FGEN;SLRX;GMDA;KRUS;CYCC
- Fly Intel: Top five analyst initiations FGEN SLRX GMDA KRUS CYCC
- 04/27/2020
|
JPMorgan construction analysts to hold an amalyst/industry conference call
- JPMorgan construction analysts to hold an amalyst/industry conference call
- 04/27/2020
|
JPMorgan basic materials analysts to hold an analyst/industry conference call
- JPMorgan basic materials analysts to hold an analyst/industry conference call
- 04/27/2020
|
's Top Upgrades, Downgrades For April 27, 2020
- Upgrades
For Alliance Data Systems Corp (NYSE: ADS), Compass Point upgraded the stock from Neutral to Buy. Alliance Data Systems earned $0.75 in the first quarter...
- 04/27/2020
|
Citi bullish on reference labs in premarket analyst action
- FibroGen (NASDAQ:FGEN) initiated with Neutral rating and $45 (10% upside) price target at Bank of America.Salarius Pharmaceuticals (NASDAQ:SLRX) initiated with Buy rating at Ladenburg Thalmann. Shares
- 04/27/2020
|
FibroGen initiated with a Neutral at BofA FGEN
- FibroGen initiated with a Neutral at BofA BofA FGEN
- 04/27/2020
|
FibroGen initiated with a Neutral at BofA FGEN
- FibroGen initiated with a Neutral at BofA BofA FGEN
- 04/27/2020
|
B of A Securities Initiates Coverage On FibroGen with Neutral Rating, Announces Price Target to $45
|
FibroGen To Report First Quarter 2020 Financial Results
- SAN FRANCISCO, April 24, 2020 -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2020 financial results on Thursday, May 7, 2020. FibroGen will also conduct a.
- 04/24/2020
|
FibroGen To Report First Quarter —…—… Financial Results
|
Assenagon Asset Management S.A. Sells 14,010 Shares of FibroGen Inc (NASDAQ:FGEN)
- Assenagon Asset Management S.A. lowered its holdings in shares of FibroGen Inc (NASDAQ:FGEN) by 19.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 58,053 shares of the biopharmaceutical company’s stock after selling 14,010 shares during the quarter. Assenagon Asset Management S.A.’s holdings […]
- 04/22/2020
|
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO
- Company also exceeds offering target Continue reading...
- 04/21/2020
|
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO
- Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO, Stocks: KROS,XLRN,TSE:4503,BMY,FGEN,SRRA,IMRA,ZNTL, release date:Apr 21, 2020
- 04/21/2020
|
Ladenburg Thalmann Financial Services Inc. Decreases Stock Position in FibroGen Inc (NASDAQ:FGEN)
- Ladenburg Thalmann Financial Services Inc. lessened its position in FibroGen Inc (NASDAQ:FGEN) by 28.1% during the 4th quarter, HoldingsChannel.com reports. The fund owned 2,456 shares of the biopharmaceutical company’s stock after selling 960 shares during the quarter. Ladenburg Thalmann Financial Services Inc.’s holdings in FibroGen were worth $105,000 at the end of the most recent […]
- 04/21/2020
|
Mizuho Reiterates "Buy" Rating for FibroGen (NASDAQ:FGEN)
- FibroGen (NASDAQ:FGEN)‘s stock had its “buy” rating reissued by equities research analysts at Mizuho in a note issued to investors on Monday, TipRanks reports. They presently have a $72.00 target price on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of 87.01% from the company’s previous close. FGEN has been the […]
- 04/21/2020
|
Keros Therapeutics Shares Climb 7…% After First Post-Covid-–9 Biotech IPO
|
FibroGen (FGEN) Receives a Buy from Mizuho Securities
- In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on FibroGen (FGEN), with a price target of $72.00. The company's
- 04/20/2020
|
FibroGen (FGEN) Receives a Buy from Mizuho Securities
- In a report released today, Difei Yang from Mizuho Securities reiterated a Buy rating on FibroGen (FGEN – Research Report),
- 04/20/2020
|
FibroGen says UK High Court of Justice holds certain patents to be invalid FGEN
- FibroGen says UK High Court of Justice holds certain patents to be invalid FGEN
- 04/20/2020
|
BRIEF-Fibrogen Says UK High Court Of Justice Has Held Certain Patents Relating To Methods Of Using HIF-PHIs To Be Invalid
|
FibroGen Reports UK Court Ruling
- FibroGen, Inc. (FGEN) today announced that the United Kingdom’s High Court of Justice has held certain patents1 relating to methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) to be invalid. This decision does not affect the validity of these patents across the rest of Europe. While FibroGen is disappointed with the court’s decision, this UK ruling does not affect development or commercialization timelines for roxadustat, FibroGen’s HIF-PHI for treatment of anemia in chronic kidney disease, including in the UK or elsewhere in Europe.
- 04/20/2020
|
FibroGen Reports UK Court Ruling
- SAN FRANCISCO, April 20, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the United Kingdom’s High Court of Justice has held...
- 04/20/2020
|
FibroGen Announces UK Has Held Certain Patents Relating To 'methods of using hypoxia-inducible factor prolyl hydroxylase inhibitors' To Be Invalid; Ruling Does Not Affect Validity Of Patents In Rest Of Europe
|
Arden Trust Co Invests $115,000 in FibroGen Inc (NASDAQ:FGEN)
- Arden Trust Co acquired a new position in shares of FibroGen Inc (NASDAQ:FGEN) in the 1st quarter, HoldingsChannel reports. The fund acquired 3,317 shares of the biopharmaceutical company’s stock, valued at approximately $115,000. Several other large investors have also added to or reduced their stakes in FGEN. Neo Ivy Capital Management acquired a new position […]
- 04/19/2020
|
Bailard Inc. Grows Holdings in FibroGen Inc (NASDAQ:FGEN)
- Bailard Inc. lifted its holdings in FibroGen Inc (NASDAQ:FGEN) by 29.6% during the first quarter, Holdings Channel reports. The institutional investor owned 13,143 shares of the biopharmaceutical company’s stock after acquiring an additional 3,000 shares during the quarter. Bailard Inc.’s holdings in FibroGen were worth $457,000 as of its most recent SEC filing. Other large […]
- 04/18/2020
|
Norges Bank Acquires Shares of 749,729 FibroGen Inc (NASDAQ:FGEN)
- Norges Bank acquired a new stake in FibroGen Inc (NASDAQ:FGEN) during the fourth quarter, Holdings Channel reports. The fund acquired 749,729 shares of the biopharmaceutical company’s stock, valued at approximately $32,156,000. Other hedge funds and other institutional investors also recently bought and sold shares of the company. Neo Ivy Capital Management purchased a new position […]
- 04/14/2020
|
Alliancebernstein L.P. Boosts Holdings in FibroGen Inc (NASDAQ:FGEN)
- Alliancebernstein L.P. lifted its stake in FibroGen Inc (NASDAQ:FGEN) by 0.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 116,290 shares of the biopharmaceutical company’s stock after buying an additional 400 shares during the period. Alliancebernstein L.P. owned approximately 0.13% of FibroGen […]
- 04/10/2020
|
Professor Dame Carol Black, Internationally-Renowned Physician on Connective Tissue Disorders, Joins Riptide Bioscience Advisory Board
- Riptide Bioscience, Inc., today announced that Dame Carol M. Black, FRCP, MACP, FMedSci, Foreign Associate Member of the Institute of Medicine USA, renowned clinician/scientist and eminent expert in systemic sclerosis, has joined the company’s Scientific Advisory Board (SAB).
- 04/09/2020
|
Keros upsizes IPO, raising $96M for blood and musculoskeletal trials
- Keros Therapeutics has braved a turbulent market to pull off an IPO, hitting the top end of its price range and selling 20% more shares than originally planned. The upsized IPO gives Keros the firepower to take two drugs into phase 2 in a clutch of hematological and musculoskeletal indications.
- 04/08/2020
|
Humana Inc (NYSE: HUM) Q4 2019 Earnings Call Transcript | AlphaStreet
- Ladies and gentlemen, thank you for standing by and welcome to the Humana Fourth Quarter Earnings Call.
- 04/06/2020
|
Woodstock Corp Buys Vanguard FTSE Emerging Markets, FibroGen Inc, Tesla Inc, Sells Ubiquiti ...
|
Cubist Systematic Strategies LLC Buys 20,895 Shares of FibroGen Inc (NASDAQ:FGEN)
- Cubist Systematic Strategies LLC lifted its stake in FibroGen Inc (NASDAQ:FGEN) by 121.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 38,041 shares of the biopharmaceutical company’s stock after acquiring an additional 20,895 shares during the period. Cubist Systematic Strategies LLC’s holdings in FibroGen were […]
- 04/02/2020
|
Brinker Capital Inc. Cuts Stock Holdings in FibroGen Inc (NASDAQ:FGEN)
- Brinker Capital Inc. trimmed its position in shares of FibroGen Inc (NASDAQ:FGEN) by 3.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,169 shares of the biopharmaceutical company’s stock after selling 677 shares during the quarter. Brinker Capital Inc.’s holdings in FibroGen were […]
- 04/02/2020
|
FibroGen Inc (NASDAQ:FGEN) Shares Bought by AQR Capital Management LLC
- AQR Capital Management LLC raised its holdings in FibroGen Inc (NASDAQ:FGEN) by 485.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 96,991 shares of the biopharmaceutical company’s stock after acquiring an additional 80,420 shares during the period. AQR Capital Management LLC […]
- 04/02/2020
|
Bank of New York Mellon Corp Has $49.02 Million Holdings in FibroGen Inc (NASDAQ:FGEN)
- Bank of New York Mellon Corp raised its position in FibroGen Inc (NASDAQ:FGEN) by 21.3% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,142,813 shares of the biopharmaceutical company’s stock after acquiring an additional 200,984 shares during the period. Bank of New York Mellon Corp owned approximately […]
- 03/31/2020
|
Do Hedge Funds Think SiteOne Landscape Supply, Inc. (SITE) Is A Good Stock To Buy?
- Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
- 03/28/2020
|
Hedge Funds Were Buying AppFolio Inc (APPF) Before The Coronavirus
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/27/2020
|
Hedge Funds Were Buying ASGN Incorporated (ASGN) Before The Coronavirus
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/27/2020
|
Hedge Funds Were Buying SAGE Therapeutics Inc (SAGE) Before The Coronavirus
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/27/2020
|
Hedge Funds Were Selling FibroGen Inc (FGEN) Before The Coronavirus
- We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P; 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
- 03/27/2020
|
Mizuho Securities Maintains a Buy Rating on FibroGen (FGEN)
- Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN) today and set a price target of $72.00. The company's shares closed last
- 03/27/2020
|
Mizuho Securities Maintains a Buy Rating on FibroGen (FGEN)
- Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN – Research Report) today and set a price
- 03/27/2020
|
FibroGen (NASDAQ:FGEN) Cut to D at TheStreet
- TheStreet lowered shares of FibroGen (NASDAQ:FGEN) from a c- rating to a d rating in a research note published on Tuesday, TheStreetRatingsTable reports. A number of other research analysts have also issued reports on FGEN. BidaskClub lowered FibroGen from a hold rating to a sell rating in a research report on Wednesday, March 18th. Zacks […]
- 03/27/2020
|
AstraZeneca's Lokelma Gets Approval in Japan for Hyperkalaemia
- The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.
- 03/26/2020
|
Goldman Sachs Group Inc. Buys 174,518 Shares of FibroGen Inc (NASDAQ:FGEN)
- Goldman Sachs Group Inc. grew its stake in shares of FibroGen Inc (NASDAQ:FGEN) by 20.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,048,453 shares of the biopharmaceutical company’s stock after buying an additional 174,518 shares during the […]
- 03/26/2020
|
Envestnet Asset Management Inc. Reduces Stake in FibroGen Inc (NASDAQ:FGEN)
- Envestnet Asset Management Inc. lowered its stake in FibroGen Inc (NASDAQ:FGEN) by 6.4% in the 4th quarter, HoldingsChannel reports. The fund owned 20,894 shares of the biopharmaceutical company’s stock after selling 1,440 shares during the period. Envestnet Asset Management Inc.’s holdings in FibroGen were worth $896,000 at the end of the most recent quarter. Other […]
- 03/25/2020
|
Thomas F. Kearns, Jr. Sells 18,000 Shares of FibroGen Inc (NASDAQ:FGEN) Stock
- FibroGen Inc (NASDAQ:FGEN) Director Thomas F. Kearns, Jr. sold 18,000 shares of the company’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $23.17, for a total value of $417,060.00. Following the sale, the director now owns 161,464 shares of the company’s stock, valued at […]
- 03/25/2020
|
BRIEF-Fibrogen Inc Signs Agreement For Bulk Manufacture/Supply Of Roxadustat
|
Biotech stocks have held up better than the broader market — and these five are potential winners
- Favor large-cap stocks with decent sales and high cash levels.
- 03/24/2020
|
FibroGen Inc (NASDAQ:FGEN) Receives Average Rating of "Hold" from Brokerages
- Shares of FibroGen Inc (NASDAQ:FGEN) have been assigned an average recommendation of “Hold” from the nine ratings firms that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. The average […]
- 03/22/2020
|
Christine Chung Sells 7,345 Shares of FibroGen Inc (NASDAQ:FGEN) Stock
- FibroGen Inc (NASDAQ:FGEN) SVP Christine Chung sold 7,345 shares of the company’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $25.91, for a total transaction of $190,308.95. Following the transaction, the senior vice president now owns 122,518 shares in the company, valued at approximately $3,174,441.38. The […]
- 03/21/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ: BMRA ) Centogene NV (NASDAQ: CNTG ) Gilead Sciences, Inc. (NASDAQ: GILD ) Imara Inc (NASDAQ: IMRA ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Down In The Dumps (Biotech stocks that hit 52-week lows March 19.) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aikido Pharma Inc (NASDAQ: AIKI ) Alpine Immune Sciences Inc (NASDAQ: ALPN ) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Anika Therapeutics Inc (NASDAQ: ANIK ) Anixa Biosciences Inc (NASDAQ: ANIX ) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Antares Pharma Inc (NASDAQ: ATRS ) Apyx Medical Corp (NASDAQ: APYX ) Arca Biopharma Inc (NASDAQ: ABIO ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) aTyr Pharma Inc (NASDAQ: LIFE ) AVEO Pharmaceuticals, Inc.
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
Stocks That Hit 52-Week Lows On Thursday
- On Thursday morning, 1178 companies hit new 52-week lows.
Facts of Interest:
The largest company by market cap to set a new 52-week low was Nuveen Preferred & Income...
- 03/19/2020
|
FibroGen price target lowered to $51 from $65 at Citi FGEN
- FibroGen price target lowered to $51 from $65 at Citi Citi FGEN
- 03/19/2020
|
FibroGen Inc (NASDAQ:FGEN) CFO Pat Cotroneo Sells 9,239 Shares
- FibroGen Inc (NASDAQ:FGEN) CFO Pat Cotroneo sold 9,239 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $26.36, for a total value of $243,540.04. Following the completion of the sale, the chief financial officer now owns 245,705 shares in the company, […]
- 03/19/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
FibroGen (NASDAQ:FGEN) Downgraded to Sell at BidaskClub
- FibroGen (NASDAQ:FGEN) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. A number of other brokerages also recently issued reports on FGEN. ValuEngine upgraded FibroGen from a “hold” rating to a “buy” rating in a report on […]
- 03/18/2020
|
Citigroup Inc. Lowers Stock Position in FibroGen Inc (NASDAQ:FGEN)
- Citigroup Inc. cut its stake in shares of FibroGen Inc (NASDAQ:FGEN) by 57.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 43,842 shares of the biopharmaceutical company’s stock after selling 58,928 shares during the quarter. Citigroup Inc.’s holdings in FibroGen were worth $1,880,000 at the end of the most recent quarter. Several […]
- 03/14/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Stocks That Hit 52-Week Lows On Thursday
|
$67.97 Million in Sales Expected for FibroGen Inc (NASDAQ:FGEN) This Quarter
- Equities research analysts expect that FibroGen Inc (NASDAQ:FGEN) will report $67.97 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for FibroGen’s earnings. The lowest sales estimate is $23.00 million and the highest is $92.60 million. FibroGen reported sales of $23.86 million in the same quarter last year, which […]
- 03/09/2020
|
Mackay Shields LLC Trims Stock Position in FibroGen Inc (NASDAQ:FGEN)
- Mackay Shields LLC decreased its stake in FibroGen Inc (NASDAQ:FGEN) by 3.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 56,005 shares of the biopharmaceutical company’s stock after selling 2,100 shares during the period. Mackay Shields LLC owned 0.06% of […]
- 03/07/2020
|
Q1 2020 Earnings Forecast for FibroGen Inc Issued By Piper Sandler (NASDAQ:FGEN)
- FibroGen Inc (NASDAQ:FGEN) – Research analysts at Piper Sandler boosted their Q1 2020 earnings per share estimates for FibroGen in a report issued on Monday, March 2nd. Piper Sandler analyst D. Brill now anticipates that the biopharmaceutical company will post earnings per share of ($0.22) for the quarter, up from their prior estimate of ($0.64). […]
- 03/06/2020
|
Q1 2020 Earnings Forecast for FibroGen Inc (NASDAQ:FGEN) Issued By Svb Leerink
- FibroGen Inc (NASDAQ:FGEN) – Svb Leerink decreased their Q1 2020 earnings per share estimates for shares of FibroGen in a report released on Tuesday, March 3rd. Svb Leerink analyst G. Porges now forecasts that the biopharmaceutical company will earn ($0.28) per share for the quarter, down from their previous estimate of ($0.17). Svb Leerink also […]
- 03/05/2020
|
FibroGen Inc (NASDAQ:FGEN) to Post Q1 2020 Earnings of ($0.50) Per Share, William Blair Forecasts
- FibroGen Inc (NASDAQ:FGEN) – Investment analysts at William Blair issued their Q1 2020 earnings estimates for shares of FibroGen in a report released on Tuesday, March 3rd. William Blair analyst A. Hsieh expects that the biopharmaceutical company will post earnings of ($0.50) per share for the quarter. William Blair also issued estimates for FibroGen’s Q2 […]
- 03/05/2020
|
FibroGen, Inc. Just Released Its Annual Earnings: Here’s What Analysts Think
- Last week, you might have seen that FibroGen, Inc. (NASDAQ:FGEN) released its annual result to the market. The early...
- 03/04/2020
|
Here's What Analysts Are Forecasting For FibroGen, Inc. After Its Full-Year Results
- Last week, you might have seen that FibroGen, Inc. (NASDAQ:FGEN) released its annual result to the market. The early...
- 03/04/2020
|
FibroGen (NASDAQ:FGEN) Trading Down 8.6% After Earnings Miss
- FibroGen Inc (NASDAQ:FGEN) shares dropped 8.6% on Tuesday following a dissappointing earnings announcement. The stock traded as low as $38.44 and last traded at $39.46, approximately 1,804,508 shares were traded during mid-day trading. An increase of 198% from the average daily volume of 604,850 shares. The stock had previously closed at $43.15. The biopharmaceutical company […]
- 03/04/2020
|
Edited Transcript of FGEN earnings conference call or presentation 2-Mar-20 10:00pm GMT
- Q4 2019 FibroGen Inc Earnings Call
- 03/04/2020
|
After coronavirus shutdown, S.F. drugmaker reopens China plants in time for major product push
- Eyeing a market of millions of chronic kidney disease patients — and with a favorable reimbursement decision in China that took effect Jan. 1— the company is readying a major sales and education effort aimed at hospitals and doctors.
- 03/03/2020
|
Novartis Leads $100M Round for Fibrosis-Focused Pliant Therapeutics
- When Novartis signed on as a partner to Pliant Therapeutics last fall, it also agreed to eventually take an equity stake in the smaller biotech. The Swiss
- 03/03/2020
|
Edited Transcript of FGEN earnings conference call or presentation 2-Mar-20 10:00pm GMT
- Q4 2019 FibroGen Inc Earnings Call
- 03/03/2020
|
One Thing To Remember About The FibroGen, Inc. (NASDAQ:FGEN) Share Price
- Anyone researching FibroGen, Inc. (NASDAQ:FGEN) might want to consider the historical volatility of the share price...
- 03/03/2020
|
FibroGen (FGEN) Receives a Buy from Mizuho Securities
- Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN) today and set a price target of $72.00. The company's shares closed last
- 03/03/2020
|
FibroGen (FGEN) Receives a Buy from Mizuho Securities
- Mizuho Securities analyst Difei Yang maintained a Buy rating on FibroGen (FGEN – Research Report) today and set a price
- 03/03/2020
|
